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Virulence and biofilm formation in Candida albicans are inhibited by short
peptide subunits of EntV

Shane Alan Cristy, B.S.

Advisory Professor: Michael C. Lorenz, Ph.D.

Candida albicans, the most clinically significant fungal pathogen, commonly
causes topical mucosal infections such as oral cavity and urogenital tract infections. It
also less frequently causes severe invasive and bloodstream infections. Invasive
infections are most prevalent amongst patients with compromised innate immune
responses, such as those receiving chemotherapy or recovering from surgery. C.
albicans can also form biofilms on implanted medical devices. Fungal infections are
difficult to treat due to the paucity of therapeutic options, and this problem is
compounded by the resistance properties of biofilm infections.
Candida albicans exists as a member of the commensal flora of the skin and gut
where many complex polymicrobial interactions occur with genera such as
Pseudomonas and Streptococcus. Some of these interactions potentiate or inhibit
virulence. One such interaction is with Enterococcus faecalis, a bacterial
gastrointestinal commensal species. E. faecalis produces a small peptide, EntV, that
modulates C. albicans virulence. The mature 68-amino acid EntV peptide inhibits
biofilm formation in vitro and attenuates fungal virulence in a Caenorhabditis elegans
infection model and a murine oral candidiasis model.
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In this work, I sought to identify the regions of EntV responsible for the antifungal activity, and based on structural information, I hypothesized that the activity is
localized to a single helix of the mature peptide. In this study, I report that smaller
peptides derived from this helix ranging from 12 to 16 amino acids have equal or
improved efficacy in inhibiting C. albicans virulence and biofilm formation. These
smaller peptides inhibit initial adhesion to abiotic surfaces, reduce final biofilm biomass,
and reduce the size of mature biofilms as measured by confocal microscopy. Further
trimming of these peptides to fewer than 11 amino acids reduces and eventually
eliminates activity. These data indicate that EntV-derived peptides warrant further
investigation as potential non-fungicidal additives to medical devices and antifungal
therapeutics.
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Chapter 1: Background and Significance

1

Candida albicans
Candida albicans is an opportunistic fungal pathogen that causes
oropharyngeal, vulvovaginal, and systemic disseminated infections (1, 2). C. albicans
is commonly isolated from the commensal flora of the oral cavity, genitourinary tract,
and gastrointestinal tract (3). As such, it is generally not communicated from person to
person; rather, the source of infection is often the patient’s own microbiota (4). As a
member of the commensal microbiota, C. albicans has many complex interactions with
other microbes in the host environment that potentiate or inhibit virulence (5–7). In
healthy individuals, the phagocytes of the innate immune system and barrier defenses
of mucosal surfaces prevent C. albicans overgrowth and infection (8).
This pathogen is remarkable for its phenotypic polymorphism, a key virulence
trait. In response to environmental conditions, it can switch between growing as a
budding ovoid yeast, elongated segmented pseudohyphae, and multinucleated
filamentous hyphae (9). Additionally, C. albicans can form biofilms on abiotic and host
surfaces (10). For some critically ill patients, the growth of a biofilm on a contaminated
central venous catheter is the greatest risk factor for developing a dangerous
bloodborne C. albicans infection (11–13). Due to a paucity of options in effective
antifungal therapies to treat C. albicans infections, drug discovery is an important
subject of active research in the field (10, 14, 15).
Pathology of Candidiasis
Candida albicans causes many different infections in the human host. These
include skin infections such as candidal intertrigo (16) and eye infections such as
endogenous endophthalmitis (17). Some chronic mucocutaneous candidiasis
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disorders even have host genetic predispositions (18). However, oropharyngeal,
vulvovaginal, and disseminated candidiasis are the most clinically important infections
caused by C. albicans.
Oropharyngeal Candidiasis
Oropharyngeal candidiasis, or thrush, is a mucosal infection of the tongue and
palate caused by an overgrowth of Candida species, of which C. albicans is the most
common (1). These infections are common in neonates, especially those delivered
preterm, due to their immature immune systems and lack of a healthy and diverse
microbiome (19, 20). Adults with healthy immune systems and microbiomes rarely
experience oropharyngeal infections (1, 20). However, persons with weakened
immune systems, such as those living with HIV, are much more likely to develop an
oropharyngeal candidiasis infection. Thrush is described as an AIDS-defining illness,
meaning if a patient presents to the clinic with thrush and is otherwise healthy, they
should additionally be tested for HIV (21). Lastly, other factors that may put a person at
risk for an oral thrush infection include the presence of dental implants, radiation
therapy or chemotherapy to the head or neck, and the use of broad-spectrum
antibiotics (1, 20). Generally, the prognosis for these infections is good. If a relapse
infection occurs, this is often due to poor compliance with prescribed therapy or
because the predisposing factors still exist (1).
Vulvovaginal Candidiasis
Candida species are the second most frequent cause of vulvovaginitis behind
the overgrowth of bacterial species such as Gardnerella vaginalis and Mycoplasma
hominis (22). Vulvovaginal candidiasis infections are caused by the overgrowth of
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Candida species. Estimates have indicated up to 75% of women will experience at
least one infection in their lifetime. The vast majority of these infections are caused by
Candida albicans, but Candida glabrata is also etiological (22). In addition to
overgrowth of Candida species, vulvovaginal candidiasis is characterized by irritation
and inflammation of the vulva and vaginal mucosa and neutrophil infiltration to the site
of infection (2, 23).
Vulvovaginal candidiasis is generally not considered to be a sexually transmitted
disease as it is typically caused by the overgrowth of native flora (22). Several risk
factors have been indicated including underlying diabetes, immunosuppressive
therapies, antibiotic treatment, pregnancy, and oral contraceptive use (2, 22). Infections
caused by C. albicans are typically uncomplicated and can be cleared by treatment
with fluconazole. Recurring vulvovaginal candidiasis, defined as at least four infection
events in a single year, is an idiopathic chronic overgrowth of Candida species that
results in irritation and inflammation and requires maintenance therapy with antifungals
to control symptoms (22). Of women who experience vulvovaginal candidiasis
infections, only approximately 5-8% will contract a recurring infection (24).
Disseminated Candidiasis
Unlike the mucosal infections, disseminated candidiasis infections are rarer and
more dangerous. In the year 2000 the United States diagnosed approximately 10,000
candidemia cases with a 10% attributable mortality in pediatric patients and a 14.5%
attributable mortality in adult patients with a median crude mortality rate of 32% (25).
Furthermore, the incidence of bloodstream infections (BSIs) caused by Candida
species has risen since that measure, making Candida species the fourth leading

4

cause of nosocomial BSIs in the United States (26). There are two main sources of the
infection: the gastrointestinal tract and the skin (8).
C. albicans can translocate from the gastrointestinal tract to the bloodstream due
to abdominal surgery or the introduction of medical devices that disrupt the mucosal
barrier (4). The gastrointestinal tract also tends to be the origin of disseminated
infections in patients receiving treatment that affects quickly dividing cells. Patients
with a hematological malignancy, receiving chemotherapy, or undergoing a
hematopoietic stem cell transplant are at elevated risk for these infections. These
patients are usually taking antibiotics, may have mucositis from chemotherapy, are
immunosuppressed generally, and specifically may be neutropenic (25, 27, 28).
Together, these conditions create an environment conducive to Candida overgrowth in
the intestinal lumen and translocation to the bloodstream (29). Once bloodborne, the
fungal cells invade host tissue. For the vast majority of these patients, the major
organs most affected are the liver and spleen, while the kidneys are affected to a lesser
degree (30).
Candidemia due to a translocation of fungal cells from the skin to the
bloodstream is most often found in nonneutropenic acutely ill patients in intensive care
units (25). Fungal contamination of central venous catheters is the primary route of
translocation from the skin into the bloodstream of these patients (8, 11). Central
venous catheters are an essential medical device, and over 5 million devices are
inserted into patients annually in the United States (11). However, they are a major risk
factor because they compromise the skin barrier and are infected frequently. There is
a strong correlation, but not a strictly causal relationship, such that of all the
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candidemia cases, 65 – 90% of these patients have a central venous catheter (12).
Autopsy results have shown that the kidneys are the primary organs affected by skinderived candidemia (8).
In addition to the liver, spleen, and kidneys (8, 30), bloodborne C. albicans can
invade the heart and central nervous system (31, 32). Once the infection is spread
across the deep tissues of the host, it can be extremely difficult to treat. The infection
may manifest into sepsis, meningitis, endocarditis, or total organ failure accompanied
by crude mortality rates of 25 – 60% (31–34).
Polymorphism
There is a common but oversimplified view in the field that yeast is the
commensal, noninvasive, even nonpathogenic morphology of C. albicans while hyphae
are the pathogenic form of medical concern (9). Rather, it is the switching between
yeast and hyphal forms that is essential for full C. albicans virulence (35). This is
evidenced by the attenuated virulence of mutants locked in either the yeast (Δ/Δ
efg1/efg1 Δ/Δ cph1/cph1 (36)) or the hyphal (Δ/Δ tup1/tup1, Δ/Δ nrg1/nrg1 (37)) forms.
Hyphal formation is characteristic of invasive infections (38–41). In mucosal
infections, hyphae have been shown to adhere to the surface of epithelial cells and
puncture the tissue; this activity has been shown in esophageal infections (40),
vulvovaginal infections (38), and in the intestines (41). In disseminated infections,
hyphae cause tissue damage throughout the body including the heart (31), kidneys,
and the blood-brain barrier (39). Additionally, after phagocytosis by a macrophage,
hyphal morphogenesis promotes C. albicans escape from the phagosome and
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macrophage lysis (42). Hyphal morphogenesis is not induced after phagocytosis by a
neutrophil, however, and no such escape or cell killing occurs (43).
The yeast form has been shown to be advantageous in the early stages of
dissemination by establishing infection sites throughout the body of the host (35). It is
unlikely that yeast cells in circulation arise from invading hyphal cells transitioning to
yeast, as serum is a potent inducer of hyphal morphogenesis (44). Rather, these yeast
cells may enter systemic circulation by translocation from where C. albicans grows
commensally in the gut (45) and on the skin (46). Disperser cells from a mature biofilm
are another source of yeast that can enter the circulation if the biofilm is growing on an
implanted medical device such as a central venous catheter (9).
Biofilms
C. albicans can form biofilms on a variety of biotic and abiotic surfaces including
medical devices. C. albicans can easily colonize and form biofilms on devices
introduced to places in the body where it grows as a commensal, such as dentures in
the oral cavity or a urinary catheter to the urogenital tract (11, 13, 47). Regular and
thorough cleaning are usually sufficient to limit biofilm growth on dentures (1), but
infected urinary catheters must be removed and a subsequent antifungal regimen is
sometimes required (11, 13). Candida biofilm infections of surgically implanted medical
devices such as mechanical heart valves, pacemakers, and hip and knee joint
prostheses are comparatively rare, but these infections carry higher rates of associated
mortality. The infected device must be removed in an invasive surgery, unless doing
so puts the patient at undo hazard (11, 13), followed by a lengthy regimen of antifungal
treatment (48).
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For nonneutropenic immunocompetent patients, the use of a central venous
catheter is the greatest risk factor for developing candidemia (11–13). Additionally, of
these infections caused by C. albicans and C. parapsilosis, biofilm production has been
shown to correlate with a significant increase in mortality (49). For patients receiving
nutrition by intravenous hyperalimentation, these two fungal species are of particular
concern because the glucose in the media promotes biofilm formation (49). Disperser
cells from these biofilms are given instant access to the bloodstream (9), and treatment
necessitates removal of the catheter and a lengthy antifungal regimen (13, 48, 49).
Biofilm Structure and Development
The structure of a C. albicans biofilm is remarkably heterogenous. Typical
biofilms grown on an approximately level surface have a densely packed foundational
layer of yeast and pseudohyphal cells. Hyphae encased in extracellular matrix
components grow out from the foundation (50–53). The total structure can be variable
in size, but biofilms have been measured up to 450 µm thick (50).
The first step of biofilm development is adhesion to the substrate. This
interaction is mediated by adhesins, proteins that protrude from the fungal cell wall to
bind to the substrate either electrostatically or with specific cell surface receptors (54–
57). Many C. albicans adhesins are glycosylphosphatidylinositol-dependent cell wall
proteins with N-terminal domains that mediate substrate binding and characteristic
serine/threonine-rich tandem repeat domains. C. albicans adhesins include Eap1 (56),
Hwp1 (58), Iff4 (59), Hyr1 (60), and several of the Als proteins, notably Als1 and Als3
(54).
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Of the adhesins mentioned, yeast cells express Eap1 and Als1 (55–57). Hyphal
cells additionally produce the Hwp1, Iff4, Hyr1, and Als3 adhesins (57–59, 61, 62).
There is a logical assumption in the field that all these adhesins are strong promoters of
virulence due to their activity in fungal attachment to host tissue and establishment of
invasive infections and biofilms (63). There is evidence that Iff4 and Hwp1 are
essential for virulence in murine disseminated or oroesophageal models, respectively
(58, 59). This evidence remains somewhat circumstantial. This uncertainty is likely
because there are many adhesins in C. albicans, potentially some unknown as well,
and deletion of only one allows for compensation by others.
Having established contact with the surface, the yeast cells rapidly change their
transcription regulation framework. This process is dynamic with many overlapping
pathways and yet undiscovered factors, but the end result of this change is to activate
biofilm specific genes and stimulate hyphal morphogenesis (54, 55, 64, 65).
One of the first changes to occur is activation of the cell integrity mitogenactivated protein (MAP) kinase pathway by accumulating active MAP kinase Mpk1p
(also called Slt2p). This initial contact-dependent step activates the PKC pathway with
Pkc1, and a downstream target of Pkc1 is MAPK Mkc1 (66). Mkc1 is a critical effector
that is necessary for virulence in systemic infections (67) and putatively interacts with
Bcr1 and Efg1 (55, 64). Bcr1 is one of a set of a master biofilm regulators that has
several downstream targets including Als1, Als3, and Hwp1 (54). In the context of
biofilms, all three of these adhesins are important for fungal cell-cell adherence,
creating a more cohesive structure (57, 62).
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There are three well characterized signaling cascade pathways that serve as the
primary positive promoters of hyphal morphogenesis in C. albicans: the cyclic AMP
(cAMP) pathway, MAP-kinase pathway, and Rim101 pH response pathway (64, 65,
68). Of these, the cAMP pathway is most influential for clinically relevant biofilm
development (69). The cAMP pathway responds to many different environmental
conditions including the accumulation of CO2 in the form of bicarbonate (70). Ras1
activates Cyr1, an adenylate cyclase, which produces cAMP. Two isoforms of cAMPdependent protein kinase, Tpk1 and Tpk2, then phosphorylate Efg1 (65, 68, 69, 71).
The master regulators of biofilm formation identified so far are Efg1, Bcr1, Brg1,
Rob1, Ndt80, Tec1, Flo8, Rfx2, and Gal4 (51, 72). These regulators have an intricate
web of interactions with each other and regulate approximately 1,000 target genes (51).
Efg1 has multiple functional domains and regulates transcription in response to various
environmental cues (73). Deletion of efg1 results in a mutant that is still capable of
forming hyphae, but further manipulation to create a Δ/Δ efg1/efg1 Δ/Δ cph1/cph1
mutant locks C. albicans in a yeast form (36).
As the hyphae continue to grow, the filamentation transcription framework is
maintained by Ume6 (74–76), a transcription factor that has been shown to work
downstream of several of the master regulators (75). Ume6 has an oppositional
equilibrating relationship with two transcriptional repressors, Nrg1 and Rfp1, along with
their mutual co-repressor, Tup1. This creates a negative feedback loop without which
C. albicans uncontrollably forms hyphae under non-inducing conditions (74, 75, 77).
In addition to forming hyphae, as the biofilm grows it produces extracellular
matrix (ECM) components. The majority of the ECM is made of polysaccharides
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similar in composition to the fungal cell wall (50). Biofilm cells have been found to have
cell walls with a greater proportion of β-1,3 glucan, and the surrounding matrix contains
significant amounts of β-1,3 glucan (78). The β-1,3 glucan in the biofilm matrix is most
likely due to increased β-glucan synthase (Fks1p) activity. The matrix is successful in
sequestering antifungal drugs, including drugs from all three major classes of
antifungals, thus rendering C. albicans biofilms less susceptible to antifungal treatment
(79, 80).
The final development stage of biofilm formation is when the biofilm seeds
disperser cells into the media. In the context of a biofilm growing in an implanted
central venous catheter, these cells will be the ones to cause a disseminated infection
(9, 81). Interestingly, disperser cells have been shown to be phenotypically distinct
from C. albicans cells grown planktonically. Disperser cells more readily adhere to new
substrates and are more virulent in a disseminated model of disease (81).
Antifungal Treatment in Clinical Practice
There are currently three classes of antifungal drugs approved for clinical use
against invasive or systemic candidiasis by the FDA. These drugs target either
ergosterol, a unique fungal membrane component, or the production of the fungal cell
wall (82). There are few available antifungal drugs because fungi are more closely
related to mammals evolutionarily than bacteria or viruses, thus we share more
common cellular features. This similarity increases the odds of toxicity and off target
effects (83).
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Polyenes
Polyenes were the first class of antifungals approved for clinical use and are
derived from natural products of the bacterial genus Streptomyces (84). This class
includes nystatin, a common topical treatment for mucocutaneous candidiasis. The
polyenes used to treat invasive or systemic infections are amphotericin B and its lipid
formulations (83). Amphotericin B interacts with ergosterol in the fungal membrane and
forms an eight-member ring-shaped pore. Accumulation of these pores results in
fungal membrane permeability and ultimately cell death (85, 86).
Amphotericin B is typically reserved for patients with special situations such as
Candida meningitis or those who cannot tolerate or are not responding to therapy with
echinocandins (82). This is because amphotericin B frequently causes adverse effects
ranging from mild symptoms such as nausea and fever (83) to severe and potentially
chronic symptoms including nephrotoxicity. Reports of acute renal failure can be as
high as between 50 – 65% of patients receiving treatment. Amphotericin B continues
to be used as a last line of defense despite the severe side effects due to its potent
efficacy against most Candida species (82, 87).
Azoles
Azole drugs inhibit fungal growth and alter membrane integrity by directly
inhibiting the ergosterol biosynthesis enzyme lanosterol 14α-demethylase (85, 88).
The azole class can be separated into two subclasses: the imidazoles and the
triazoles. The imidazoles include miconazole, clotrimazole, and ketoconazole and are
used to treat mucocutaneous candidiasis (83). The triazoles approved by the FDA to
treat systemic infections are fluconazole and voriconazole (82), however there are
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many new drugs of this class in development (83). These drugs have generally good
safety profiles and low toxicity (88). Per the current clinical guidelines, fluconazole may
be used as a front-line drug for invasive candidiasis, especially against a C.
parapsilosis infection. Furthermore, once laboratory results have positively identified
the fungal agent, fluconazole is recommended against C. albicans and C. tropicalis
species, and voriconazole may be appropriate for treating C. krusei and C. glabrata
infections (89). While there has not been a significant shift in the incidence of azole
resistant C. albicans isolates, that has not been the case across the rest of the Candida
genus as other species develop resistance to these widely used drugs (90).
Echinocandins
Echinocandins are the most recently developed class of antifungals. These
drugs are fungicidal and are active to a narrower spectrum of mostly Candida and
Aspergillus species. Echinocandins inhibit fungal wall biosynthesis by inactivating β-1,
3-D-glucan synthase (Fks1) (91). Of this class, caspofungin, micafungin, and
anidulafungin are all FDA approved for treatment of systemic candidiasis (82), and all
three of these drugs have excellent safety profiles with little to no adverse effects (92).
These drugs are the current preferred front-line options available to treat any moderate
to severe invasive candidiasis infection (89).
Combination therapy
It remains unclear if combinations of the antifungal drugs listed thus far would
provide any benefit when treating invasive candidiasis. A randomized clinical trial
tested combinations of amphotericin B and fluconazole against monotherapy
fluconazole and showed positive results for the combination therapy (93). However,
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many leaders in the field have suggested this study had some methodological flaws
(82, 94). Further study is necessary to determine if a combination of antifungal drugs
would be advantageous for the treatment of invasive candidiasis (82); unfortunately,
clinical trials of this kind are difficult to conduct due to many challenges including
expense, time, low enrollment numbers, and the critical nature of the disease (95). In
vitro and in vivo studies have been conducted, but these studies have produced
inconsistent results, occasionally finding antagonism between different drugs (96).
For Candida meningitis, endophthalmitis, and endocarditis, current guidelines
suggest a combination of amphotericin B and flucytosine, an antimetabolite drug (89).
Flucytosine is not used as a monotherapy due to concerns about the development of
resistance (83). From a survey of approximately 400 patients in the United States, 11 –
35% of C. albicans isolates have developed resistance to flucytosine (97).
Prophylactic treatment
In the recent decades, clinicians have used prophylactic administration of
antifungals, especially azoles, to protect vulnerable patients from fungal infections.
Many different types of patients may receive this therapy ranging from those with a
recent abdominal surgery or a chronic hematological disease to recipients of stem cell
or organ transplants (48, 98, 99). This treatment has been effective in reducing the
incidence of invasive fungal infections in this vulnerable population (98–100); however,
there are concerns about the development of resistance against these drugs.
Prophylactic azole treatment has been associated with an increase in the risk of
colonization with resistant isolates and an increase in colonization with non-albicans
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Candida species such as C. glabrata or C. krusei, which are innately resistant to
fluconazole, or C. dubliniensis which has largely acquired fluconazole resistance (100).
Current Antifungal Limitations and Future Directions
Currently there are few options available for treatment of invasive candidiasis.
Current guidelines in the United States outline only the nine drugs mentioned
previously, and of those choices, four are amphotericin B formulations that carry severe
risk of adverse effects, and the others comprise only two chemical classes (89), thus
making the chance of resistance a critical concern. To address the urgent need of new
antifungal agents, one possibility to pursue is the targeting of fungal virulence factors
such as the formation of hyphae or biofilms. An agent created for this strategy would
attenuate virulence rather than inhibit fungal growth and thus reduce the selective
pressure for the generation of resistant mutants. Small molecule inhibitors have
already been identified that show promising results exemplifying these key
characteristics (14).
Antimicrobial Peptides
Antimicrobial peptides (AMPs) have been previously broadly defined as
chemicals with either killing or static activity against microbes and that are comprised of
amino acids with peptide bonds (101). AMPs can be conjugated with non-amino acid
moieties and can range in size from large proteins to a few amino acids. The field of
antifungal AMPs is less developed than that for antibacterial AMPs (101), but AMPs
have been established as a legitimate avenue for future pharmacological discoveries
(102).
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Most AMPs can be categorized into one of three groups based upon their target
and mechanism of action. AMPs that are active against C. albicans typically target
either the membrane, the fungal cell wall, or nucleic acid biosynthesis and metabolism
(101, 103). I have curated a noncomprehensive list of AMPs that are active against C.
albicans for the purpose of emphasizing important discoveries in the field and
demonstrating the state of antifungal peptide research.
Membrane-active peptides
AMPs that form pores in the cell membrane are common in nature. Production
of these peptides has been identified in a wide variety of species including plantassociated bacteria, sheep, and honey bees (101). Pore-forming AMPs tend to be
effective against a broad range of microorganisms. This lack of specificity can manifest
as high toxicity when used in clinical applications (104). Amphotericin B and LL-37, an
AMP produced by neutrophils, are both AMPs that interact with fungal cell membranes
to form pores (86, 105). Human neutrophils and epithelial cells produce β-defensins
that are secreted from the salivary glands (106). β-defensins HBD-1 and HBD-3
permeabilize membranes via an ATP-independent mechanism (107).
Not all AMPs that target the cell membrane form pores. One such example of
interest is aureobasidin A, a cyclic depsipeptide produced by Aureobasidium pullulans
(108). Aureobasidin A is a noncompetitive inhibitor of the essential sphingolipid
biosynthesis enzyme inositol phosphorylceramide synthase (109, 110). This enzyme is
not present in mammalian cells, so the peptide has a low toxicity profile (111).
Aureobasidin A is potent against Candida species, but it has minimal efficacy against
Aspergillus species due to increased efflux activity in Aspergillus (110, 112).
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Cell Wall targeting AMPs
The echinocandin class of antifungals discussed previously are AMPs
synthetically derived from secondary metabolites produced by several fungal species
(113). The echinocandins approved to treat candidemia, caspofungin, micafungin, and
anidulafungin, are all cyclic lipopeptides with two proline residues (114). While isolates
resistant to these drugs are rare, there are concerns about resistance because
modification of a few amino acids of the target enzyme, Fks1, can increase the MIC of
these drugs 100 to 1,000-fold (115). In vitro resistance studies of these drugs with C.
albicans have shown a paradoxical effect where growth is reduced at the MIC, but then
continues at concentrations above the MIC, and then halts at much higher
concentrations. A leading hypothesis to explain this effect is that activation of stress
response pathways can compensate to maintain cell wall stability, but whether this has
any clinical relevance is undetermined as there is insufficient evidence of this effect in
clinical datasets or in vivo models (114)
Another cell wall targeting AMP of interest is nikkomycin Z. This dipeptide
synthesized by Streptomyces tendae is a competitive inhibitor of chitin synthases (116).
Chitin is formed from β-(1,4) linkages of N-acetylglucosamine and is an essential
component of the fungal cell wall (117). Chitin is of particular interest for fungal
pathogenesis because hyphal cell walls contain approximately 10 times more chitin
than yeast cells (118). Nikkomycin Z is fungicidal against C. albicans, but when used
as a monotherapy it is lacking in potency. When used in combination with fluconazole,
itraconazole, caspofungin, or micafungin, however, the drug synergizes to improve the
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efficacy of these existing antifungals against C. albicans growing planktonically and as
a biofilm (119, 120).
AMP nucleic acid inhibitors
Bovine neutrophils produce a tridecapeptide amide, indolicidin, that binds DNA
and potentially has activity against DNA processing and repair (121, 122). This peptide
causes some toxicity to human cells, so recent studies have investigated potential
formulations with gold nanoparticles and graphene to develop the peptide into a
potential pharmaceutical product (123, 124).
Other AMPs
Histatin 5 is a cationic peptide found in human salivary glands that is effective
against many Candida species (125). This peptide binds to Ssa1/2 on the fungal cell
wall and induces reactive oxygen species formation upon translocation into the cell
(126–129). A 12-amino-acid product of Histatin 5 has been created that retains the
anti-Candida activity (130, 131).
Current developments in AMP research
In recent years three antifungal peptides have been tested in clinical trials:
aureobasidin A, nikkomycin Z, and VL-2397, which is primarily active against
Aspergillus species (132). If approved for clinical use, these drugs would make
available entirely new classes of antifungals.
The AMPs discussed here target fundamental properties of the cell, such as the
charge of the membrane, that are typically difficult to alter, and any alterations made
are often metabolically taxing (133). Additionally, the concentration range of AMPs that
is conducive to selection of single-step, drug-resistant mutants is narrower than that of
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conventional antimicrobials (134). The total of these effects is an overall lower
probability of developing resistance (135). Therefore, AMPs are an attractive source
for potential antifungal drugs and agents for use in combination therapy with
conventional antifungals (133).
Resistance is not impossible, however. Resistance events have been described
against both naturally occurring and pharmaceutical AMPs (103, 136, 137). The
resistance strategies used against AMPs are not dissimilar to those used against
conventional antimicrobials. C. albicans may acquire resistance to AMPs by secreting
effectors to degrade the peptide, producing AMP efflux pumps, or by differential
regulation of signaling pathways (138). Due to the threat of resistance, a strategy of
particular interest would be to combine the advantages of AMPs with those of
attenuation therapies. This strategy could potentially further reduce the selective
pressure for development of resistance.
In general, the selective pressure to evolve AMPs stems from competition.
From the perspective of the host, AMPs are used to protect against infection and
cultivate the commensal microbiota (139). Many members of the commensal gut
microbiota are intrinsically resistant to AMPs produced by the host in response to
infection (140). For microbes, AMPs present a means to gain a competitive edge in
their environment (141).
Interspecies interactions with Candida albicans
C. albicans has many complex interactions with other microbes in the host
environment that potentiate or inhibit virulence (5–7). These interactions occur as both
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direct physical contact (5, 142) and chemical signaling with quorum sensing
mechanisms (142).
Pseudomonas aeruginosa and Candida albicans
P. aeruginosa is a Gram-negative opportunistic pathogen that produces several
virulence factors (143). It is motile, rod-shaped, and capable of forming biofilms (144).
P. aeruginosa and C. albicans are often co-isolated in cystic fibrosis lung infections and
burn wound infections (6, 145–147). In in vitro studies, P. aeruginosa physically
interacts with C. albicans by adhering to hyphal cells and then secreting
phospholipases and phenazines, killing the fungal cells (148–150). P. aeruginosa also
interacts with C. albicans chemically. A P. aeruginosa quorum sensing signaling
molecule, 3-oxo-12 homoserine lactone is chemically similar to farnesol, a C. albicans
quorum sensing signal molecule (55, 151). This signaling molecule from P. aeruginosa
can trigger an inactivation of the Ras1-cAMP-PKA pathway, thus reducing the
expression of hyphal and biofilm genes (151–154). In turn, farnesol from C. albicans
has been shown to interact with P. aeruginosa quorum sensing and reduce the
production of phenazines (155).
Streptococci and Candida albicans
Streptococcus mutans is a Gram-positive colonizer of the oral cavity that is
commonly co-isolated with C. albicans from the denture plaques of healthy individuals
and pediatric dental caries (156, 157). S. mutans produces a competence-stimulating
peptide and a signaling molecule, trans-2-decenoic acid, that both inhibit hyphal
formation in C. albicans. In turn, S. mutans quorum sensing is stimulated by C.
albicans (158).
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When forming dental plaques, C. albicans adheres to and aggregates with
Streptococci such as S. mutans, S. salivarius, and S. gordonii. This physical
interaction is mediated by the Als adhesins (159). S. gordonii directly interacts with
Als1 and Als3 with its SspA and SspB surface proteins. Interaction with S. gordonii
promotes C. albicans hyphal morphogenesis and biofilm formation (160–162).
Enterococcus faecalis and Candida albicans
Enterococcus faecalis is a Gram-positive opportunistic pathogen that causes
several infections including endocarditis, bacteremia, urinary tract, and intra-abdominal
infections. It is a member of the commensal gut microbiome as early as infancy (163).
C. albicans and E. faecalis are commonly co-isolated likely due to their shared niche in
the gastrointestinal tract (164–166). These species have been co-isolated from
infected root canal samples (167) and blood samples from patients in intensive care
(168). Intra-abdominal infections, typically the result of loss of gastrointestinal tract
integrity, are the most frequent source of polymicrobial blood stream infections (169–
172).
In the gut of healthy individuals, E. faecalis and C. albicans grow as benign
commensals (3, 163). This type of growth can be demonstrated in in vivo models. In a
Caenorhabditis elegans infection model, monocultures of C. albicans and E. faecalis
were found to cause disease, but co-cultures of the two microbes attenuated the
virulence of each (173). Furthermore, the addition of spent E. faecalis supernatant to in
vitro cultures of C. albicans inhibited hyphal formation and reduced the biomass of
biofilms (173). The inhibition of C. albicans by E. faecalis was found to be mediated by
an antimicrobial peptide, EntV (15).
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EntV
EntV is the product of E. faecalis gene ef1097 (15, 174). This bacteriocin has
bactericidal activity against members of the Gram-positive genera Lactobacilli and
Staphylococcus, including Staphylococcus aureus (174, 175). Its production is
regulated by the Fsr quorum-sensing system (173, 175), and it is secreted from the cell
as a 136-amino-acid (-aa) propeptide (176). A putative E. faecalis thioredoxin, DsbA,
then catalyzes the formation of disulfide bond between C106 and C167, and the aminoterminus is cleaved by the extracellular E. faecalis metalloprotease GelE. This
processing is necessary to produce the antifungally active 68aa EntV peptide (176).
This peptide is non-toxic to C. albicans but has been shown to attenuate fungal
virulence traits. In vitro analyses showed EntV to have activity in reducing C. albicans
hyphal morphogenesis and biofilm formation. EntV showed protection in a C. elegans
infection model; treatment with concentrations of EntV ranging from 10 nM to 0.001 nM
were all effective in reducing hyphal penetration into the cuticle of the nematodes and
extending the lifespan relative to untreated infected nematodes. EntV also showed
protection in a murine macrophage coculture model and was non-toxic toward the
macrophages or HeLa cells. Lastly, EntV has been shown to reduce pathology in a
murine oropharyngeal candidiasis model. In this experiment, the authors gave mice a
sublingual inoculation of C. albicans and then allowed them to drink freely from water
that either contained EntV or the vehicle control. After three and five days the mice
were euthanized and tongues were collected for histology and fungal burden analysis.
The mice provided with water containing 100 nM EntV showed fewer signs of fungal
invasion into the epithelium, less disruption of the epithelium, and a significant
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decrease in fungal burden (15). These results indicate that EntV is a potent inhibitor of
C. albicans virulence and a strong candidate for further study as a potential antifungal
therapy. The mechanism of action for the attenuation activity of EntV against C.
albicans is undefined, but this is an active subject of research.
Our lab is interested in optimizing the EntV peptide into a viable pharmaceutical
product. One objective in service to this goal is to find a substructure within the 68aa
peptide that achieves the antifungal activities. The 68aa structure is suboptimal
because of the necessity of the disulfide bond and its large size, but a single peptide
structure of approximately twelve amino acids would be more in accordance with other
antimicrobial peptides currently in clinical use or under investigation (101).
Our lab conducted an analysis of the structure of EntV that is currently
unpublished. In this analysis, we found that the 136aa structure consists of a ring of
helices around a central helix which happens to be the C-terminal region. Upon
cleavage of the N-terminus by GelE, the ring is opened up, resulting in a 68aa
structure, and the central C-terminal helix is exposed. This insight led to my central
hypothesis that small peptides derived from this central helix will have equal to
improved efficacy in inhibiting C. albicans in vitro biofilm formation and ex vivo
virulence.
In this thesis I show that a 16aa peptide derived from the C-terminal central helix
of EntV had greater potency in inhibiting C. albicans adhesion than the 68aa EntV
peptide. This 16aa peptide had similar activity to the 68aa EntV peptide in altering C.
albicans biofilm structure, reducing biofilm biomass, and inhibiting virulence in an ex
vivo epithelial tissue invasion model. The EntV peptide and the C-terminal helix-
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derived peptide were found to be highly specific for inhibiting biofilm formation in C.
albicans. Lastly, a peptide of minimum size that retains the efficacy of the C-terminal
helix was determined.
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Chapter 2: Materials and Methods
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Strain, media, and growth conditions
All strains used in this work are detailed in Table 2.2. For general growth and
propagation, C. albicans strains were grown in yeast extract peptone dextrose (YPD)
medium (1% yeast extract, 2% peptone, 2% glucose) (177) at 30°C and shaking at 200
rpm. Biofilm assays were performed in artificial saliva media (YNB-AS) modified from
Wong & Sissions (178) (0.17% yeast nitrogen base without ammonium sulfate and
amino acids (YNB) (w/v), 0.5% casamino acids (w/v), 0.25% mucin (porcine stomach
mucin type III, Sigma) (w/v), 14mM potassium chloride, 8 mM sodium chloride, 100 µM
choline chloride, 50 µM sodium citrate, 5 µM ascorbate) (15).
Peptides
The peptides in this study were designed by members of the Garsin and Lorenz
labs and synthetically made and purchased from Bio-Synthesis, Inc, Lewisville, Texas,
USA. These peptides were dissolved in dimethyl sulfoxide (DMSO) at a concentration
of 1 mM for stocking purposes and stored at -80°C. The peptide solution in DMSO can
be diluted directly into media for use in the assays described in this section. Table 2.1
describes the amino acid sequences of each peptide in the study starting from the
amino terminus and ending at the carboxy terminus.
Table 2.1: Peptides used in this study
Peptide Identity

Amino acid sequence

68 amino acid EntV LGSCVANKIKDEFFAMISISAIVKAAQKKAWKELAVTVLRFAKA
derivative (68aa)

NGLKTNAIIVAGQLALWAVQCGLS

16 amino acid EntV
AIIVAGQLALWAVQCG
derivative (16aa)
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12 amino acid EntV
VAGQLALWAVQC
derivative (12aa)
11 amino acid EntV
AGQLALWAVQC
derivative (11aa)
10 amino acid EntV
GQLALWAVQC
derivative (10aa)
9 amino acid EntV
QLALWAVQC
derivative (9aa)
16 amino acid
VGALWICGLAVIQAAQ
helical peptide
16 amino acid
AAAAQQGGIICLLVVW
disordered peptide
Q – I variant

AIIVAGILALWAVICG

Q – E variant

AIIVAGELALWAVECG
KVVADEKTSITSEYTIEEQRQIDEVAAVLEKMFADGVTEENLK
QYAQANYSEEELIIADNELNTNLSQIQDENAIMYKVDWGALG

Sam57
NCMANKIKDELLAMISVGTIIKYAQKKAWKELAKIVIKYVAKAG
VKTNAALIAGQLAIWGLQCGINF
AETPAAVESAGTVDEQALAQYFAKVDNAQTEKEAHDALVDFL
GEDAANQAIKENSATGQSVSTRGAGTFLTCIKGKASDDIKSV
YpkK
FDVNVVAAAIGQKDYAKAAKEAVKYLAKQGVKRNAAALAGM
FAYWGWQCRGSW
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Growth Assay
Growth of C. albicans strain SC5314 with the peptides used in this study was
assayed using a similar technique as described previously (179) with the following
modifications. SC5314 was grown overnight in YPD at 30°C and shaking at 200 rpm
and subsequently subcultured for 4 hours in the same growth conditions. Cells were
then collected and washed twice in phosphate-buffered saline (PBS). The cell
concentration was adjusted in YPD such that the starting OD600 of the assay would be
0.01. Each peptide was added to YPD media for a final concentration of 100 nM. Cells
and peptides were added together to clear 96 well polystyrene plates (Falcon) with a
total media volume of 200 µl along with a media only contamination/negative control
and a DMSO vector control. The plate was incubated at 30°C with continuous shaking
for 16 hours, and OD600 measurements were taken automatically every 15 minutes on
a Synergy H1 plate reader (BioTek) with Gen5 version 3.08 software (BioTek).
Adhesion Assay
The C. albicans adhesion assay was developed using similar techniques as
described previously (180) with the following specifications. C. albicans strains
SC5314 and Δ/Δ efg1 Δ/Δ cph1 were grown overnight at 30°C and shaking at 200 rpm
and subsequently subcultured for 4 hours in the same growth conditions. Cells were
then collected, washed twice in phosphate-buffered saline (PBS), and adjusted to a
concentration of 1 x 107 cells/ml in PBS (or PBS with peptide additions) (measured with
Countess II, Life Technologies). The peptides were prepared in a dilution series with
final concentrations of 100 nM, 10 nM, 1 nM, 0.1 nM, 0.01 nM, and 0.001 nM. The C.
albicans cells were then soaked in the PBS peptide solution for 60 minutes at 30°C and
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shaking at 200 rpm. Then 100 µl of this solution was added to wells of a 96 well tissue
culture treated polystyrene plate (Falcon) (for a concentration of 1 x 106 cells/well).
Technical replicates of each test condition were performed in 6 total adjacent wells.
100 µl of YNB-AS media with peptide additions at the same concentration was then
added to each well, and then the plate was incubated for 90 minutes at 37°C and
shaking at 200 rpm. After this incubation, the media was gently removed along with
any cells that failed to adhere. The remaining cells were then stained for 20 minutes
with 40 µl of 0.08% crystal violet solution (diluted, Sigma) added to each well. The
crystal violet stain was removed and the wells were washed three times with sterile
water to remove any excess dye. The cells were then destained with 200 µl of 200
proof ethanol for 20 minutes, and 100 µl of the ethanol solution was transferred to a
new well for analysis. The optical density at 595 nm (OD595) was measured using a
Synergy H1 plate reader (BioTek) with Gen5 version 3.08 software (BioTek).
For data analysis, the background absorbance was determined by including a
series of media only control wells. This background was then subtracted from the
values of all the samples, and the data was normalized against the untreated control.
For the experimental wells, the data was presented as a percentage relative to the
untreated control. These experiments were replicated in at least biological triplicate,
and the normalized data was analyzed in a two-way ANOVA with a Dunnett’s test to
determine differences between the untreated control and the experimental samples.
Statistical analysis was performed using GraphPad Prism 9.1 software.
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Crystal Violet Biofilm Assay
The crystal violet biofilm assay was developed using a similar technique as
described previously (15, 180) with the following specifications. C. albicans strains
SC5314 and Δ/Δ efg1 Δ/Δ cph1 were grown overnight in YPD medium at 30°C and
shaking at 200 rpm. Cells were then collected, washed twice in phosphate-buffered
saline (PBS), and adjusted to a concentration of 5 x 106 cells/ml in PBS (or PBS with
peptide additions) (measured with Countess II automated cell counter, Life
Technologies). The peptides were prepared in a dilution series with final
concentrations of 100 nM, 10 nM, 1 nM, and 0.1 nM. The C. albicans cells were then
soaked in the PBS peptide solution for 60 minutes at 30°C and shaking at 200 rpm.
Then 100 µl of this solution was added to wells of a 96 well tissue culture treated
polystyrene plate (Falcon) (for a concentration of 5 x 105 cells/well). Technical
replicates of each test condition were performed in 6 total adjacent wells, and duplicate
plates were made to ensure against the chance of contamination. The plate was then
incubated for 60 minutes at 37°C and shaking at 200 rpm. The PBS and cells that
failed to adhere were gently removed, and 200 µl of YNB-AS media with the same
peptide dilution series was added to each well. The plate was then incubated statically
at 37°C for 48 hours. After incubation, the remaining media, planktonic cells, and
pellicle were removed, leaving only the surface associated biofilm. This was stained
with 50 µl of 0.08% crystal violet solution (diluted, Sigma) for 30 minutes. The crystal
violet staining solution was removed, and then the plate was washed 4 times using an
automated 405 TS Microplate washer (BioTek). The program parameters were set with
an aspiration travel speed of 4.1 mm / second and 300 µl wash volume dispensed at
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flow rate setting 3. The biofilms were then destained with 200 µl of 200 proof ethanol
for 20 minutes, and 50 µl of the resultant was transferred to a new well, diluted with 100
µl of ethanol, and analyzed. The optical density at 595 nm (OD595) was measured
using a Synergy H1 plate reader (BioTek) with Gen5 version 3.08 software (BioTek).
For data analysis, the background absorbance was determined by including a
series of media only control wells. This background was then subtracted from the
values of all the samples, and the data was normalized against the untreated control.
For the experimental wells, the data was presented as a percentage relative to the
untreated control. These experiments were replicated in at least biological triplicate,
and the normalized data was analyzed in a two-way ANOVA with a Dunnett’s test to
determine differences between the untreated control and the experimental samples.
Statistical analysis was performed using GraphPad Prism 9.1 software.
Biofilm confocal microscopy
C. albicans biofilms were examined with confocal microscopy using a similar
technique as described previously (15) with the following specifications. C. albicans
strain HWP1p-GFP, ADH1p-mCherry was grown overnight at 30°C and shaking at 200
rpm. Cells were then collected, washed twice in phosphate-buffered saline (PBS), and
adjusted to a concentration of 5 x 106 cells/ml in PBS (or PBS with peptide additions)
(measured with Countess II, Life Technologies). The peptides were prepared at a
concentration of 300 nM. The C. albicans cells were then soaked in the PBS peptide
solution for 60 minutes at 30°C and shaking at 200 rpm. Then 100 µl of this solution
was added to wells of a tissue culture treated 8 well chamber slide (Ibidi) (for a
concentration of 5 x 105 cells/well). At least 2 technical replicates were performed for
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each biological replicate. Then 200 µl of YNB-AS media with peptide additions at the
same concentration was added to each well, and the slide was incubated statically for
48 hours at 37°C. After incubation, the biofilms were washed once with PBS to remove
planktonic cells.
Z-stacked microscopic images were taken of the biofilms using an Olympus IX83
inverted microscope with cellSens Dimension 2.3 (Olympus) software. The z-stack
images were taken at 20x magnification and had 101 vertical frames. Each frame was
separated by 3 µm, creating an image of totaling 300 µm in depth. Each image was
created using fluorescence microscopy, and if possible, these images were
deconvoluted for final presentation.
Epithelial invasion assay
Human pharyngeal carcinoma cells (FaDu) of cell line HTB-43 (ATCC,
Manassas, Virgina, USA) were cultured in Dulbecco’s Modified Eagle’s Medium
(DMEM) (GE Life Sciences) + 10% fetal bovine serum (FBS), phenol red pH indicator,
penicillin, and streptomycin at 37°C in a 5% CO2 humidified incubator. These cells
were washed with PBS, counted (measured with Countess II, Life Technologies), and
adjusted to a concentration of 1.5 x 105 cells/ml in fresh DMEM culture media. 100 µl
of these cells (for a concentration of 1.5 x 104 cells/well) were added to each well of an
8 well chamber slide (Ibidi) along with 200 µl of fresh DMEM culture media. These
cultures were allowed to grow for 2 to 3 days until each well contained a completely
confluent single layer of cells.
A C. albicans strain (JRC58B) constitutively producing mCherry from the ACT1
promoter (ACT1p-mCherry) was grown overnight at 30°C and shaking at 200 rpm.
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Cells were then collected, washed twice in phosphate-buffered saline (PBS), and
adjusted to a concentration of 2.5 x 105 cells/ml in PBS (or PBS with peptide additions)
(measured with Countess II, Life Technologies). The peptides were prepared at a
concentration of 300 nM. The C. albicans cells were then soaked in the PBS peptide
solution for 60 minutes at 30°C and shaking at 200 rpm. Then 100 µl of this solution
was added to wells of a tissue culture treated 8 well chamber slide (Ibidi) (for a
concentration of 2.5 x 104 cells/well). At least 2 technical replicates were performed for
each biological replicate. Then 200 µl of DMEM media with peptide additions only (no
FBS, phenol red, etc.) at the same concentration was added to each well, and the slide
was incubated statically for 2 hours at 37°C in a 5% CO2 humidified incubator.
After incubation the media was removed and the cells were fixed with 2.7%
paraformaldehyde for 20 minutes. The cell layer was then washed three times with
PBS and then incubated with PBS-diluted NucBlue Fixed Cell Stain (Thermo Fisher –
Life Technologies Corp. Eugene, Oregon, USA) and a polyclonal anti-Candida-FITC
antibody (LifeSpan BioSciences, Inc) overnight at 4°C and gentle rocking. The
following day, fluorescent and differential interference contrast images were taken
using an Olympus IX83 inverted microscope with cellSens Dimension 2.3 (Olympus)
software.
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Table 2.2 – Candida albicans strains in this study
Source /
Strain

Designation

Relevant Genotype

Reference

SC5314

Wild Type

Prototroph

(181)

HLC54

Δ/Δ efg1 Δ/Δ cph1

ura3::1 imm434/ura3:: 1 imm434

(36)

cph1::hisG/cph1::hisG
efg1::hisG/efg1::hisG-URA3-hisG
CEGC1

JRC58B

HWP1p-GFP,

ura3/ura3ENO1/eno1::HWP1p-GFP-URA3

ADH1p-mCherry

RPS10/rps10::ADH1p-mCherry-SAT1

ACT1p-mCherry

RPS10/rps10::ACT1p-mCherry-SAT1

(15)

Unpublished
from John R.
Collette

The three mutant strains, HLC54, CEGC1, and JRC58B were all created from the
SC5314 parent strain.

34

Chapter 3: EntV derivatives inhibit in vitro adhesion
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Introduction
The first step of biofilm formation is adhesion to the substrate. C. albicans uses
adhesins that bind to specific cell surface receptors or interact electrostatically with an
abiotic substrate to mediate adhesion (54–57). Many C. albicans adhesins are
glycosylphosphatidylinositol-dependent cell wall proteins with N-terminal domains that
mediate substrate binding. Yeast cells produce adhesins such as Eap1 and Als1, while
hyphae produce additional adhesions including Als3 and Hwp1 (55–57). Once a cell
establishes contact with a surface, it will rapidly change its transcription regulation
framework. There are many different transcription factors and pathways involved in
this change, some of which remain poorly understood, that ultimately initiate the
activation of biofilm specific genes and stimulate hyphal morphogenesis and biofilm
formation (54, 55, 64, 65).
The data presented in this chapter focus on the analysis of a novel peptide
inhibitor of the initial adherence to an abiotic substrate, specifically a tissue culture
treated polystyrene 96 well plate. The adhesion assays were conducted in artificial
saliva media (YNB-AS) as modified from Wong & Sissions (178). This medium
contains amino acids as the sole carbon source and 0.25% mucin (w/v) (15) (for further
information, refer to Chapter 2). The presence of amino acids as a carbon source has
been shown to stimulate hyphal development in C. albicans (179), and this exact
medium has been previously shown to be capable of stimulating hyphal development
(15).
The YNB-AS medium is intended to be a sufficient representation of the oral
environment (178). The range of catabolites available in the human oral environment is
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quite vast and variable between persons (182–184). However, the full range of
catabolites is not necessary to grow physiologically relevant microbial structures. The
medium used in Wong & Sissions was shown to support physiologically relevant
representations of oral biofilms such as dental plaque (178). The importance of using
YNB-AS in this study is that this media replicates a clinically important niche of C.
albicans infection and has direct relevance to murine oropharyngeal candidiasis, the
dominant in vivo infection model used in our lab.
An important component of the YNB-AS media is the dissolved porcine stomach
type III mucin. C. albicans is able to bind and adhere to mucins, although the
molecular mechanism remains unknown (185, 186). Mucins contain fucose glycans, a
known binding partner of the N-terminal region of Als1 (187) and likely binding partner
of the structurally similar Als3 adhesin (185). Hwp1 also has the potential to bind to
mucins as it is known to bind to host buccal epithelial cells (188) and have
complementary activity with Als1 and Als3 in surface adhesion (57).
In this chapter, the activity of peptides derived from the C-terminal helix domain
of EntV are tested in inhibiting C. albicans adherence to an abiotic substrate. This
analysis includes examinations of the predicted structures of these derived peptides
and an examination of structure and sequence specificity of the interaction between C.
albicans and the derived peptides. The specificity of the interaction between C.
albicans and EntV is examined using alternative bacteriocin peptides. Lastly, a peptide
of optimal activity and minimal length is determined.
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Results
It has been previously shown that the 68aa EntV peptide does not inhibit the
growth of C. albicans but has a potent effect on inhibiting fungal virulence and the
development of C. albicans biofilms (15). I hypothesized that the C-terminal helix of
EntV causes the attenuation activity. Figure 1.1A shows the amino acid sequence
starting with the N-terminus of the 68aa peptide (15, 174, 175) with the derived 16aa
peptide in red font. I used PEP-FOLD 3 (189–191), a de novo peptide structure
prediction software available online, to predict the structure of the 16aa peptide. The
dominant model predicted a helix that incorporated all available residues (Figure 3.1B),
which is consistent with the conformation of these residues in the 68aa structure (data
unpublished). However, three alternative models were generated that collectively
indicated instability at the N-terminus with disagreement on whether the valine at
position 4 would be included in the helix. Thus, these models produced peptides with
the first 3 to 4 residues forming a disorganized N-terminal tail (Figure 3.1C).
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Figure 3.1: Structure of a 16aa peptide derived from the C-terminal region of
EntV. The portion of the full EntV peptide responsible for the attenuation activity
against C. albicans was hypothesized to be the C-terminal helix. A) The amino acid
sequence of the fully processed C-terminal region of EntV is listed with the 16aa region
of interest identified in red text. B) The structure of this 16aa peptide in physiological
conditions was predicted using PEP-FOLD 3 (189–191). The dominant model
indicated a structure with all the residues forming a helix. C) From this same analysis,
alternative models predicted a structure with the first 3-4 residues forming a
disorganized N-terminal tail.
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The 16aa EntV peptide is a non-fungicidal inhibitor of C. albicans adhesion
To determine if the central, C-terminal helix of EntV is responsible for the
attenuation activity, I compared the 68aa EntV peptide with the 16aa peptide derived
from the C-terminus thereof in biofilm development assays. The 68aa peptide has
been previously shown to have no cytotoxic effect on C. albicans (15), so I verified that
this was true of the 16aa peptide as well. I performed a growth assay to assess any
toxic effects that may exist against the C. albicans prototrophic strain SC5314 cultured
in YPD media. The 68aa and 16aa peptides were diluted to a final concentration of
100 nM in YPD media, and a volumetrically equivalent DMSO only control was included
to verify that the DMSO solvent did not contribute to any toxicity. By this analysis, the
peptides cause no toxicity to the planktonic C. albicans cells (Figure 3.2A), so any
differences in biofilm development found in subsequent assays are from legitimate
inhibition effects.
The first step of biofilm development is adhesion to the substrate. I performed
adhesion inhibition assays to compare the effect of the 68aa and 16aa peptides.
These were compared against the untreated control. In addition, a Δ/Δ efg1 Δ/Δ cph1
mutant sample was included to serve as a negative control because this mutant is
known to be deficient in biofilm formation and virulence (36). These assays measured
adhesion to an abiotic substrate, i.e., the base of the well of a tissue culture treated 96well plate, and artificial saliva media was used to improve the assay’s practical
relevance. The adhesion step takes place during a 90-minute incubation period at
37°C with rotation at 200 rpm. Adhesion is measured by staining the adhered cells with
crystal violet and then ultimately measuring absorbance. The results are normalized
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relative to the untreated sample, and these normalized results can be compared across
multiple biological replicates.
The 68aa peptide effectively reduced fungal adherence at concentrations of 100
nM and 10 nM (Figure 3.2B). The 16aa peptide, however, outperformed the larger
peptide at the 100 nM and 10 nM concentrations; the 16aa peptide was sufficiently
active at these concentrations to result in adhesion inhibition comparable to the Δ/Δ
efg1 Δ/Δ cph1 mutant. Additionally, the 16aa peptide showed potent inhibition at a
concentration of 1 nM (Figure 3.2C). For a clear and thorough comparison of the two
peptides, the mean relative adhesion values for the 100 nM to 0.1 nM treated samples
from both adhesion assays are depicted in Figure 3.2D.
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Figure 3.2: The 16aa EntV peptide is a non-fungicidal inhibitor of C. albicans
adhesion. A) The 16aa and 68aa peptides at 100 nM and a DMSO vector control
were tested for inhibition of planktonic growth in YPD. Readings were done
automatically at 15 minute intervals on a plate reader. B) Adhesion to an abiotic
substrate was tested in tissue culture treated 96 well plates with artificial saliva during a
90-minute incubation period. The 68aa peptide significantly reduced adhesion at
concentrations of 100 nM and 10 nM. C) Using the same adhesion assay conditions,
the 16aa peptide was effective in reducing adhesion at concentrations of 100 nM, 10
nM, and 1 nM, and additionally this peptide was more effective at the higher
concentrations than the 68aa peptide. D) The mean relative adhesion values for the
100 nM to 0.1 nM treated samples from both adhesion assays are displayed for
comparison. Adhesion assays were analyzed by normalizing each experimental
technical replicate against the untreated mean. Results represent data collected
across three biological replicates, and a two-way ANOVA with a Dunnet’s test was
used to determine differences between the untreated control and the experimental
groups. N=3, * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001.
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The effect of the 16aa EntV peptide is sequence-specific
In the interest of rigor, two alternative hypotheses were generated to explain the
inhibition demonstrated in Figure 3.2. These alternative hypotheses challenged the
specificity of the 16aa EntV peptide. The first hypothesis is that any peptide of similar
amino acid composition and overall charge would elicit the same response. To test this
hypothesis, our lab created a disordered peptide with the same amino acid composition
as the 16aa EntV peptide, but the sequence was arranged such that all the distinct
amino acids were grouped together. This peptide is predicted to have a highly
disorganized structure according to my analysis with the PEP-FOLD 3 (189–191)
software. All models generated agreed that the only significant secondary structure is
an N-terminal helix consisting of the alanine residues and, in the dominant model, the
first glutamine (Figure 3.3A).
The second alternative hypothesis is that any peptide of similar amino acid
composition, charge, and the ability to form a helix would elicit the same response. As
before, a peptide was created from the same amino acids as the 16aa EntV peptide,
but this time carefully rearranged such as to create a peptide that is predicted to form a
similar helix as the 16aa EntV peptide. The dominant model predicted by PEP-FOLD 3
(189–191) produced a helix that incorporated all the available amino acid residues
(Figure 3.3B). Alternative models suggested instability in the helix at the tryptophan
residue, thus creating an N-terminal tail of 5 amino acid residues. Thus, this
engineered 16aa sequence variant peptide is predicted to have a structure very similar
to the EntV derived 16aa peptide.
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These peptides were tested in a growth assay as before to ensure neither
caused any cytotoxic effects (Figure 3.3C). In the adhesion assay, the disordered
peptide showed a mean inhibition of approximately 19% at the 100 nM concentration
(p-value < 0.0001) and 9% at the 10 nM concentration (p-value = 0.0434) (Figure
3.3D). The helical peptide had slightly better efficacy at the 100 nM concentration with
a mean inhibition of 27% (p-value < 0.0001), but the 10 nM concentration showed no
significant inhibition (Figure 3.3E). Overall, neither of these peptides had an inhibitory
effect comparable to the 16aa EntV peptide (Figure 3.3F). Thus. the two alternative
hypotheses were rejected. This demonstrates that the 16aa EntV peptide has a
sequence specific activity against C. albicans adhesion.
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Figure 3.3: The 16aa EntV peptide has a sequence specific inhibitory effect on C.
albicans adhesion. To test the sequence specificity of the interaction with the 16aa
EntV peptide, two alternative peptides were designed using reordered sequences of
the same amino acids as the 16aa EntV peptide. A) The disordered peptide is
predicted to be highly disorganized with only a small N-terminal helix predicted by PEPFOLD 3 (189–191). B) The helical peptide is predicted to form a helix that is likely to
incorporate the full peptide sequence but with some N-terminal instability similar to the
results with the 16aa EntV peptide. C) The peptides cause no cytotoxic effects at 100
nM concentrations against C. albicans growing planktonically in YPD. D and E)
Adhesion assays were performed with the disordered and helical peptides,
respectively. F) The activities of the disordered and helical peptides are compared with
the native 16aa EntV peptide. Adhesion assays were analyzed by normalizing each
experimental technical replicate against the untreated mean. Results represent data
collected across three biological replicates, and a two-way ANOVA with a Dunnet’s test
was used to determine differences between the untreated control and the experimental
groups. N=3, * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001.
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The attenuation activity of EntV is unique amongst similar bacteriocins
There are few antibacterial peptides produced by Gram-positive bacteria similar
to EntV that have been described previously in the literature. Two bacteriocins, Sam57
and YpkK, produced by Streptococcus pyogenes and Corynebacterium jeikeium,
respectively, share similarities of size and structural motifs with EntV. While these
peptides have only small sequence similarities, they all feature essential disulfide
bonds and C-terminal helical structures (174). I performed adhesion assays to
determine if these peptides had the same attenuation activity against C. albicans as
EntV.
Figure 3.4 depicts the results of the experiments with Sam57 and YpkK. Like
EntV, these bacteriocins had no cytotoxic effects against C. albicans (Figure 3.4A).
Both peptides showed slight efficacy at high concentrations, but neither peptide
reduced adhesion by more than 20% (Figure 3.4B and C). These results demonstrate
the specificity of EntV against C. albicans, indicating that attenuation of C. albicans
biofilm formation is a characteristic of EntV in particular, rather than of bacteriocins in
general.
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Figure 3.4: Similar bacteriocins do not greatly inhibit C. albicans adhesion. To
test the specificity of EntV compared to other similar bacteriocins, adhesion assays
were performed with the peptides Sam57 and YpkK. A) Growth in YPD was tested with
100 nM treatments of each peptide. Like EntV, these bacteriocins have no cytotoxic
effect on C. albicans. B and C) Adhesion assays were performed with the Sam57 and
YpkK peptides, respectively. D) The activities of the Sam57 and YpkK peptides are
compared to the 68aa EntV peptide. Adhesion assays were analyzed by normalizing
each experimental technical replicate against the untreated mean. Results represent
data collected across three biological replicates, and a two-way ANOVA with a
Dunnet’s test was used to determine differences between the untreated control and the
experimental groups. N=3, * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001.
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Examination of the Glutamine residues in the 16aa EntV peptide
The 16aa EntV peptide consists mostly of amino acid residues with hydrophobic
side chains. The exceptions to this are the two glutamine residues at positions 7 and
14 and the cysteine residue at position 15. The two glutamine residues are predicted
to be on the same face of the 16aa EntV peptide separated by one turn of the helix with
the leucine and tryptophan residues at positions 10 and 11 between them. The
cysteine residue has been determined to be necessary for activity in unpublished work
from the Garsin lab using the C. elegans infection assay (M. Cruz and D. Garsin,
personal communication). I hypothesized that the conspicuously placed glutamine
residues would also be necessary for EntV activity. To explore the importance of the
glutamine residues, our lab purchased two synthetic peptides with substituted amino
acid residues in the 7 and 14 positions.
The Q – I variant replaces the glutamine residues with isoleucine, a non-polar
and hydrophobic amino acid. Isoleucine was chosen because of the naturally occurring
amino acids with hydrophobic side chains, isoleucine is closest in size and shape to
glutamine. The amino acid sequence of the Q – I variant is described in Figure 3.5A
along with a predicted structure from PEP-FOLD 3 (189–191). The substituted
isoleucine residues are identified in red font, and in the structure the bright green and
red residues facing the viewer are the substituted isoleucine residues. Like the 16aa
EntV peptide, this variant peptide was predicted to form a helix that incorporated all
available amino acid residues, however unlike the 16aa EntV peptide, none of the
models generated in the prediction of this structure indicated any instability in the helix.
This variant peptide should overall be uncharged and generally be hydrophobic.
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The Q – E variant replaces the glutamine residues with glutamate, a negatively
charged amino acid. Figure 3.5B depicts the amino acid sequence of this variant
peptide along with its predicted structure. In the structure, the first member of the helix
facing the viewer (bright green) and the last member of the helix facing the viewer (red)
are the substituted glutamate residues. Interestingly, this variant peptide was predicted
to have an unstable N-terminal tail, similar to the alternative models of the 16aa EntV
peptide. All the models produced indicated instability in the N-terminus, but there was
some disagreement on if the valine at position 4 would be incorporated into the helix.
The structure depicted in Figure 3.5B does not include the valine in the helix.
The variant peptides were compared in adhesion assays depicted in Figures 3.5
C and D. The Q – I variant successfully inhibited adhesion with a reduction of
approximately 50% from the 10 nM treatment. The Q – E variant however had only a
minimal impact on adhesion with a reduction of only approximately 12% from the 100
nM treatment. The Q – I variant had activity in the same range as the 68aa EntV and
16aa EntV peptides (Figure 3.5E). The Q – E variant, however, was inactive in this
assay, but whether this is due to the permanent instability in the N-terminus of the
variant peptide or the altered overall charge of the peptide has yet to be determined.
These results indicate my hypothesis is false. The glutamine residues are not essential
for activity in inhibition of adhesion.
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Figure 3.5: Glutamine substitution variants have different activities. The activity
of the glutamine residues at positions 7 and 14 was explored using variant peptides
that substituted either isoleucine residues or glutamate residues at those positions
(indicated by red font in A and B). A) The Q – I variant is predicted to form a helix
similar to the 16aa EntV peptide. B) The Q – E variant is predicted to have an Nterminal tail consisting of at least the first three residues. C and D) Adhesion assays
were performed with the Q – I and Q – E variant peptides, respectively. E) The Q – I
variant performs in the same general range as the 68aa EntV and 16aa EntV peptides,
indicating the glutamine residues are not essential for activity. The Q – E variant
peptide, however, has only minimal activity in the assay. Adhesion assays were
analyzed by normalizing each experimental technical replicate against the untreated
mean. Results represent data collected across four biological replicates, and a twoway ANOVA with a Dunnet’s test was used to determine differences between the
untreated control and the experimental groups. N=4, * P < 0.05, ** P < 0.01, *** P <
0.001, **** P < 0.0001.
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An effective peptide of minimal size
Lastly, I hypothesized that there existed a minimum size peptide derived from
the C-terminal helix of EntV that would retain the efficacy of the 16aa EntV peptide in
inhibiting C. albicans adhesion. Previously mentioned unpublished C. elegans infection
assays from the Garsin lab indicated that the C-terminal cysteine residue is essential
for activity (M. Cruz and D. Garsin, personal communication), so the only residue that
could be removed from the C-terminus is the glycine at position 16 of the 16aa EntV
peptide. Thus, I tested peptides with progressively shorter N-termini for activity in the
adhesion assay. The amino acid sequences and predicted structures (PEP-FOLD 3
(189–191)) of the shorter peptides used in this study are depicted in Figures 3.6A
through D. All these peptides are predicted to form helices that incorporate all
available residues. The different models produced in each analysis only have minor
disagreements such as the pitch of the helix on each terminus. The peptides were
tested for cytotoxicity against C. albicans growing in YPD as before (Figure 3.6E), and
none were found to be cytotoxic.
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Figure 3.6: Small EntV peptides are predicted to form helices and are nonfungicidal. An effective peptide of minimal size was hypothesized to exist, so several
smaller peptides were described and tested for cytotoxicity against C. albicans. A
through D) The amino acid sequences and predicted structures (PEP-FOLD 3 (189–
191)) of the small peptides indicate that all these peptides form helices. E) The small
peptides were tested for cytotoxicity against C. albicans growing in YPD, and none
were found to be cytotoxic.
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Activity of small EntV peptides
The peptides described in Figure 3.6 were tested for activity in inhibiting C.
albicans adhesion. The results from the adhesion assay with the 12aa EntV peptide
(Figure 3.7A) were very similar to that of the 16aa EntV peptide (Figure 3.2C, Figure
3.7E). The 12aa EntV peptide inhibited adhesion by approximately 70% for both the
100 nM and 10 nM concentrations, and this peptide retained some efficacy at the 1 nM
concentration, inhibiting adhesion by approximately 46%. The 11aa EntV peptide was
less effective at the 100 nM concentration with an approximate inhibition of 44%, and it
lost efficacy at the 1 nM concentration level (Figure 3.7B). The 10aa EntV peptide had
a similar activity profile with slightly higher activity at the 100 nM concentration
(approximately 62% inhibition), but it lost activity at the 1 nM concentration level (Figure
3.7C). Lastly, the 9aa EntV peptide was ineffective in inhibiting C. albicans adhesion at
any concentration (Figure 3.7D).
Figure 3.7E depicts a comparison between the small peptides and the 68aa
EntV and 16aa EntV peptides. It is interesting to note from this comparison that the
12aa EntV peptide closely matched the activity of the 16aa EntV peptide while the 11aa
EntV and 10aa EntV peptides more closely matched the 68aa EntV peptide. The most
important distinctions between these peptides are potency of their activity at the 100
nM concentration and loss of activity for the 68aa EntV, 11aa EntV, and 10aa EntV
peptides at concentrations of 1 nM. In conclusion, these data indicate a peptide of
minimum size that retains the activity of the 16aa EntV peptide does exist in the 12aa
EntV peptide.
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Figure 3.7: The 12aa EntV peptide has superior activity compared to the other
small peptides. The small EntV peptides were tested in the adhesion assay to
determine if a minimum size peptide derived from the C-terminus of EntV existed that
retained EntV activity. A) The 12aa EntV peptide was a potent inhibitor of C. albicans
adhesion with similar activity to the 16aa EntV peptide. B and C) The 11aa and 10aa
EntV peptides were less effective than the 12aa EntV peptides and had activity profiles
more closely matching that of the 68aa EntV peptide. D) The 9aa EntV peptide was
ineffective at any concentration tested in inhibiting C. albicans adhesion. E) All the
activities of the small peptides are compared along with the 68aa EntV and 16aa EntV
peptides. Adhesion assays were analyzed by normalizing each experimental technical
replicate against the untreated mean. Results represent data collected across four
biological replicates, and a two-way ANOVA with a Dunnet’s test was used to
determine differences between the untreated control and the experimental groups.
N=4, * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001.
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Discussion
In this chapter I demonstrated that small peptides derived from the C-terminal
helix of EntV are capable of matching and even outperforming the activity of the 68aa
EntV peptide in inhibiting C. albicans adhesion to an abiotic substrate (Figure
3.7E). Like the 68aa EntV peptide, these small peptides are non-fungicidal (Figures
3.2A and 3.6E). The adhesion assay provided an in vitro metric by which to compare
these peptides, and by that comparison the 12aa EntV peptide was found to be the
best candidate for future study for potential pharmaceutical applications. The 12aa
EntV peptide was superior to all other peptides tested in that it was the smallest
optimally effective peptide and predicted to form a stable helix. This result informed
follow-up experiments performed by other members of the Lorenz and Garsin labs in
which the 12aa EntV peptide was tested in the murine oropharyngeal candidiasis
model. In this infection model, mice are given a sublingual inoculation of C. albicans
and allowed to drink freely from a 100 nM peptide solution in water. The mice are later
euthanized and the tongues are excised and analyzed for fungal burden and histology.
In this model the 12aa EntV peptide virtually eliminated fungal burden and performed
as well as the 68aa EntV and 16aa EntV peptides (G. Buda de Cesare, M. Cruz, and S.
Guha, personal communication).
The Introduction of this chapter included a discussion of C. albicans adhesins
and how those adhesins might interact with mucin in the YNB-AS media used in the
assay or mucin present in an in vivo oral environment. The exact molecular
mechanisms of the complex interactions between C. albicans, mucin, the substrate
surface, and EntV have yet to be elucidated. I will briefly propose a hypothetical model
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to explain the relationship between these factors and the results of the assays in this
chapter. C. albicans at the start of the adhesion stage of the experiment should be
almost uniformly in the yeast form after growth in YPD and a 1-hour soak in PBS.
These cells should begin forming hyphae due to the exposure to the YNB-AS media.
During the adhesion stage, fungal cells may bind to mucin or the substrate surface or
exist in equilibrium with both, and dissolved mucin in the media may serve as a
nucleation site for several fungal cells to bind together. Hyphae, with their greater
surface area and potentially enhanced binding to mucin and other C. albicans cells in a
mucin-centered cluster, may be able to bind to both mucin and the substrate surface,
thus depositing whole clusters of cells on the substrate surface. Cells treated with
EntV, in comparison to untreated cells, may form fewer hyphae, as has been seen in
previous studies (15, 173). With a reduction in hyphal cells, fewer independent EntV
treated cells or clustered cells around a mucin particle would adhere to the substrate.
This in vitro model would be roughly consistent with a proposed hypothetical host
mucin-shedding model whereby the host uses excess mucin shedding from the
mucosal layer to remove pathogenic microbes from a potential infection site (185).
In this chapter I extensively explored the 16aa EntV peptide and its interaction
with C. albicans adhesion, including examinations of the peptide’s predicted structure,
specificity, and potentially important residues. In Figure 3.1 I discuss that alternative
models of the 16aa EntV peptide predict that it forms an N-terminal tail consisting of 3-4
residues, which is distinct from its structure in the 68aa EntV peptide (unpublished
data). A likely hypothesis is that the unstable N-terminal residues exist in an
equilibrium between forming a tail or joining in the helical structure. This equilibrium
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state may explain some of the unique spreading of the data for the 16aa EntV adhesion
activity at low concentrations (Figure 3.2C).
In Figure 3.3 I demonstrated that the adhesion inhibition activity is sequencespecific to the 16aa EntV peptide. This is important because it indicates that C.
albicans is having a specific reaction to the presence of the C-terminal EntV peptide
sequence, and these data imply that EntV interacts with a specific, as yet unknown,
binding partner. This is further evidenced by the results in Figure 3.4 that demonstrate
that the C. albicans anti-adhesion activity of EntV is unique amongst its similar
bacteriocins.
Lastly, I explored the importance of the glutamine residues at positions 7 and 14
in the 16aa EntV peptide (Figure 3.5). Changing these residues to isoleucine residues
(Q - I variant) showed that glutamine is not necessary in these positions for
activity. However, altering the glutamine residues to glutamate residues of the opposite
charge (Q - E variant) removed activity. These results are consistent with results from
in vivo C. elegans infection assays performed in the Garsin lab (M. Cruz and D. Garsin,
personal communication). One potential explanation for this effect is that the glutamine
residues do not directly interact with the binding site, but could assist in getting the
peptide in the right position for binding. The loss of activity in the Q – E variant could
be due to the substituted glutamate residues disrupting the helical structure as
predicted by the model presented in Figure 3.5B or the change in overall charge of the
peptide.
In Figures 3.6 and 3.7 I examined the structure and activity of smaller peptides
derived from the C-terminal helix of EntV. The pattern of activity with the 12aa EntV
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peptide displaying optimal activity, the 11aa and 10aa EntV peptides displaying
suboptimal activity, and the 9aa EntV peptide being inactive is completely consistent
with in vivo experiments from the Garsin and Lorenz labs (unpublished data). This
pattern has been found in C. elegans infection assays measuring longevity of
nematodes infected with C. albicans and in the murine oropharyngeal candidiasis
model measuring fungal burden on the tongues of mice infected with C. albicans (G.
Buda de Cesare, M. Cruz, S. Guha, and D. Garsin, personal communication).
The structures of these smaller peptides, unlike the 16aa EntV peptide, were
predicted to form very stable helices. It is reasonable that the 12aa EntV peptide would
match the activity of the 16aa EntV peptide considering that the 12aa EntV essentially
consists of the portion of the 16aa EntV helix predicted to be most stable. The 12aa
EntV peptide omits the first three residues (alanine-isoleucine-isoleucine) that were
predicted to form the N-terminal tail of the 16aa EntV peptide.
A possible explanation for why the 11aa and 10aa EntV peptides exhibit
suboptimal activity compared to the 16aa and 12aa EntV peptides is that the valine in
position 1 of the 12aa EntV peptide is necessary for optimal activity either due to direct
interaction with the binding partner or by facilitating binding with the binding
partner. The 9aa EntV peptide however has no inhibitory effect at all. The likely
explanation for this is that having the glutamine, an amino acid with a polar sidechain,
at the N-terminus of the peptide creates a dipole moment that is sufficiently strong to be
incompatible with the binding site of the peptide.
Finally, one might observe a pattern that the data in Figures 3.3 and 3.4 indicate
the non-specific 16aa helix, 16aa disordered, Sam57, and YpkK peptides generally
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have slight efficacy at only the 100 nM concentrations. This likely is due to a slight
interaction with C. albicans. To rigorously ensure the DMSO vehicle could not be
explained to cause this effect, I tested the 68aa EntV and 12aa EntV peptides with
extra DMSO at each concentration to attempt to replicate the normally established
activity pattern in addition to a DMSO control. I added 0.5 μl of DMSO to each peptide
solution and the DMSO control, a larger amount than is usually present in these
experiments. The results replicated the established pattern and can be found in
Appendix Figure A.1, thus verifying that the DMSO vector does not contribute to
adhesion inhibition.
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Chapter 4: EntV derivatives reduce biofilm biomass and disrupt biofilm structure
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Introduction
The previous chapter examined effects of EntV derivatives on adhesion, the
earliest stage of biofilm development. In this chapter, the focus is instead turned to
mature biofilms in the late stages of development.
As discussed in the first chapter of this work, C. albicans creates large, complex
biofilms with heterogeneous structures consisting of C. albicans in both its yeast and
hyphal forms along with an extracellular matrix (ECM) composed primarily of
carbohydrates (50, 78). These biofilms are of particular clinical importance when they
grow on medical devices such as central venous catheters. These biofilms produce
disperser cells that can create systemic infections (9, 81) as well as a reservoir with
increased antimicrobial recalcitrance that can cause persistent infections (52, 53).
Previous work to describe the structure of C. albicans biofilms has shown that
biofilms grown on level surfaces under static conditions develop an overall architecture
characterized by a dense bed of yeast cells with hyphae growing generally vertically
out of the bed. These hyphae are encased in ECM, providing structural support to the
biofilm (50–53). However, most medical devices are not level surfaces with a static
supply of nutrients. Biofilms grown under these conditions tend to be more disordered
but are still composed of yeast and hyphae encased in a protective layer of ECM (50).
It has been shown previously that 68aa EntV is a potent inhibitor of biofilm
development. When added to either planktonic cells or young biofilms, the 68aa EntV
showed potent activity in reducing overall biomass after 48 hours (15). This previously
published work performed by members of the Garsin and Lorenz labs examined
statically grown biofilms. Our lab has since established a collaboration with David
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Andes, M.D., a leader in the field of C. albicans biofilm formation on medical devices.
Dr. Andes examined the potency of EntV in inhibiting biofilm development in the less
hospitable environment of a central venous catheter model in rats. This work
(unpublished) revealed that the 68aa EntV peptide was a potent inhibitor of biofilm
formation in this environment.
In this chapter I will compare the efficacy of 68aa EntV to derivatives of the Cterminal helix in inhibiting the development of mature biofilms. This chapter begins with
a qualitative discussion on the architecture of C. albicans biofilms, starting with
untreated biofilms and then comparing the effect of continuous treatment with 68aa
EntV and 16aa EntV on biofilm structure. Then follows a quantitative comparison of the
biomass of treated biofilms. The specificity of the effect of EntV is analyzed using
alternative peptides in quantitative biomass experiments, and lastly, the 12aa – 9aa
peptides are tested for efficacy in both the biomass and biofilm structural analyses.
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Results
To determine the efficacy of EntV derivatives against C. albicans biofilms, first I
characterized the structure of untreated biofilms. I used fluorescence microscopy to
build three-dimensional images of biofilms with C. albicans strain CEGC1 (15). This
strain produces green fluorescent protein (GFP) dependent upon activation of the
HWP1 promoter and an mCherry fluorophore dependent upon activation of the ADH1
promoter. Hwp1 is a cell wall protein expressed by hyphal cells that has adhesin
activity and is necessary for biofilm formation (57, 62). Therefore, this strain produces
mCherry constitutively and GFP only upon induction of the hyphal morphogenesis
pathways. I grew these biofilms on tissue culture treated chamber slides (Ibidi) for 48
hours in YNB-AS at 37°C. Before imaging, the biofilms were washed once with PBS to
remove planktonic cells. For the microscopy, I took z-stacked images at 20x
magnification with 101 frames and 3 µm between each frame, creating a total image
300 µm in depth. If possible, depending on signal strength, these images were
deconvoluted using cellSens Dimension 2.3 (Olympus) to increase resolution.
Figure 4.1 depicts representative images of untreated biofilms. In this figure and
subsequent microscopy figures in this chapter (Figures 4.2, 4.3, 4.8, 4.9, 4.10, and
4.11), horizontally adjacent images, e.g., 4.1A and 4.1B, depict the same image from
either a topological or y-axis viewpoint, respectively.
Overall, these untreated biofilms can be characterized as having a regular
structure with hyphae that generally extend upward into the structure of the biofilm.
The samples in Figures 4.1A/B and C/D were not deconvoluted, but from the y-axis
view of these figures (4.1B and D) it can be seen that the hyphae in these biofilms are

71

generally growing vertically. Figures 4.1E – H were successfully deconvoluted, and
with this increased resolution, many more hyphae can be distinguished. In these
figures, it is clear that the hyphal network is a dense structure consisting of hyphae that
initially grow vertically out from the yeast bed before diverging with no clear uniform
direction. Taken together, these data indicate that the upper layers of these biofilms
are dense structures that are likely well supported by ECM components. From the
topographical view images (Figures 4.1A, C, E, and G) it is clear that the biofilm
structure as a whole is cohesive with no large holes or gaps.
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Figure 4.1: Untreated biofilms have a regular structure with vertical hyphae.
Representative three-dimensional images of untreated C. albicans CEGC1 biofilms
collected by fluorescence microscopy. These biofilms were grown statically for 48
hours at 37°C in YNB-AS media and then washed. Microscopy was performed using zstacked images at 20x magnification with 101 frames and 3 µm between each frame,
creating a total image 300 µm in depth. If possible, depending on signal strength,
these images were deconvoluted using cellSens Dimension 2.3 (Olympus) to increase
resolution. Horizontally adjacent figures represent different perspective views of the
same image. A and B) This image is not deconvoluted. This biofilm is large with
hyphae that generally grow vertically out of the yeast layer. C and D) This image is not
deconvoluted. As with the previous image, the biofilm is large with vertical hyphae. E
and F) This image was successfully deconvoluted, and the increased resolution allows
for individual hyphae to be seen. G and H) This image was deconvoluted. This image
depicts a smaller than average untreated biofilm, but this biofilm is notable for its dense
hyphal layer.
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EntV disrupts biofilm structure
Previous studies have shown that EntV is effective in inhibiting biofilm growth
and reducing the size of young biofilms (addition of EntV after 24 hours) (15). For this
study of the effect of EntV on biofilm structure, biofilms were prepared and grown as
described previously but were treated with 300 nM EntV before and through the
duration of incubation. Figure 4.2 depicts representative images of biofilms treated with
68aa EntV. From this figure, 68aa EntV treated biofilms can be broadly characterized
as less cohesive and smaller with a flattened hyphal structure.
The hyphal layer for the biofilm depicted in Figures 4.2A and B is laying over
nearly horizontally, creating the characteristic flattening effect. The images in Figures
4.2C-H were successfully deconvoluted, and in Figure 4.2D the hyphae appear to start
folding over and growing horizontally almost immediately out of the yeast bed. In
Figure 4.1H, the hyphae appear to initially grow vertically from the yeast layer before
folding over. Treatment with EntV also appears to reduce the cohesiveness of the
biofilms. The biofilms in Figures 4.2A and E appear more disordered than those of the
untreated samples in Figure 4.1.
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Figure 4.2: EntV disrupts biofilm structure
Representative three-dimensional fluorescence microscopy images of C. albicans
CEGC1 biofilms treated with 300 nM 68aa EntV. These biofilms were grown statically
for 48 hours at 37°C in YNB-AS media with 68aa EntV and then washed. Microscopy
was performed using z-stacked images at 20x magnification with 101 frames and 3 µm
between each frame, creating a total image 300 µm in depth. If possible, depending on
signal strength, these images were deconvoluted using cellSens Dimension 2.3
(Olympus) to increase resolution. Horizontally adjacent figures represent different
perspective views of the same image. A and B) This image was not deconvoluted.
The hyphal layer can be seen folding over and growing generally horizontally on top of
the yeast bed. C and D) This image was deconvoluted. This biofilm appears to be
generally flattened, and the hyphae grew horizontally out of the yeast bed. E and F)
This image was deconvoluted. This biofilm appears disorganized. G and H) This
image was deconvoluted. This biofilm appears flattened. From the y-axis view (H), it
appears that the hyphae initially grew vertically from the yeast bed before falling over
and growing horizontally.
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16aa EntV derivative is effective in disrupting biofilm structure
To test my hypothesis that a peptide derived from the C-terminal helix of EntV
will be equally effective in inhibiting biofilm formation, I prepared biofilms as before and
treated them with the 16aa EntV peptide. Figure 4.3 depicts representative images of
the 16aa EntV treated biofilms. In general, the same characteristics that described the
biofilms treated with the 68aa EntV peptide can be applied to these biofilms. Biofilms
treated with the 16aa EntV peptide were generally less cohesive, smaller, and flattened
compared to untreated biofilms.
Much like the 68aa EntV treated biofilms, the samples depicted in Figures 4.3AD have hyphae that are lying down horizontally almost as a mat on top of the yeast
bed. The biofilm in Figure 4.3E appears to be highly disorganized, and the flattening
effect can be seen in the y-axis view of this biofilm (Figure 4.3F). Furthermore, in
Figure 4.3F, hyphae can be seen growing out of the yeast bed at all angles, but the
uppermost hyphae appear to lie across the whole structure as a mat. The biofilm in
Figures 4.3I and J is cohesive with a dense and orderly hyphal structure, and it shows
the characteristic flattening effect, almost identical to the biofilm depicted in Figures
4.2G and H. Lastly, the biofilm in Figures 4.3G and H shows some stochastic variation
amongst these samples. The hyphal layer of this biofilm appears more disorganized
than that of the untreated biofilms in Figures 4.1E-H, but the size appears to be
approximately the same. In summary, treatment with the 16aa EntV peptide produces
biofilms similar to those treated with the 68aa EntV peptide, which can be characterized
as being smaller, flattened, and less organized and cohesive than untreated biofilms.
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Figure 4.3: 16aa EntV disrupts biofilm structure
Representative three-dimensional fluorescence microscopy images of C. albicans
CEGC1 biofilms treated with 300 nM 16aa EntV. These biofilms were grown statically
for 48 hours at 37°C in YNB-AS media with 16aa EntV and then washed. Microscopy
was performed using z-stacked images at 20x magnification with 101 frames and 3 µm
between each frame, creating a total image 300 µm in depth. If possible, depending on
signal strength, these images were deconvoluted using cellSens Dimension 2.3
(Olympus) to increase resolution. Horizontally adjacent figures represent different
perspective views of the same image. A – D) These two images were not
deconvoluted. These biofilms appear disorganized with hyphae laying horizontally,
forming a mat over the yeast bed layer. E and F) This image was deconvoluted. This
biofilm appears disorganized with the uppermost layer of hyphae laying as a mat over
the whole structure. G and H) This image was deconvoluted. This biofilm shows the
variation in the 16aa EntV treated samples. This biofilm is large but highly
disorganized. I and J) This image was deconvoluted. This biofilm shows the
characteristic flattening effect.
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68aa EntV and 16aa EntV are effective in reducing biofilm biomass
I also developed a quantitative biomass assay to pair with the microscopy data
presented thus far. This assay measured the biomass of biofilms using a crystal violet
stain. Briefly, this experiment was performed by growing C. albicans strains SC5314
and Δ/Δ efg1 Δ/Δ cph1 statically for 48 hours at 37°C in a 96-well tissue culture treated
polystyrene plate. After incubation the remaining media, planktonic cells, and pellicle
were removed, leaving only the surface associated biofilm. This biofilm was stained
with crystal violet solution for 30 minutes, and then excess dye was washed away using
an automated Microplate washer. The biofilms were destained with 200 proof ethanol
and crystal violet absorbance was measured at OD595.
For each biological replicate I prepared 2 separate plates with 6 technical
replicates each. This was to mitigate the chance of loss due to contamination. For the
data analysis, I determined the background by including a medium-only well and
subtracted the average from the values of the samples. Data were normalized as a
percentage relative to the untreated control. A two-way ANOVA with a Dunnett’s test
was used to determine differences between the untreated control and the experimental
samples.
Figure 4.4 shows the data from the biomass assays conducted with 68aa EntV
and the 16aa EntV derivative. The 100 nM treatment with the 68aa EntV peptide
reduced biomass by approximately 24%, and this effect is roughly consistent for the 10
nM and 1 nM concentrations. The efficacy decreases at 0.1 nM with a reduction of only
approximately 12%, however the statistical difference and p-values are equivalent for
all tested concentrations (p < 0.0001) (Figure 4.4A). The 16aa EntV peptide shows a
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similar pattern of efficacy. The 100 nM treatment with 16aa EntV reduced biomass by
approximately 21%, and the effect only drops to 15% at the 0.1 nM concentration
(Figure 4.4B). Similar to the data collected from the adhesion assays in Figure 3.2C,
the lower concentrations of the 16aa EntV treatment show a spreading trend with a
greater deviation from the mean. Overall, the biomass assays show highly similar
results between treatment with the 68aa EntV peptide and 16aa EntV peptide, thus the
16aa EntV peptide is capable of producing the same inhibition effect as the full 68aa
EntV peptide.

82

Figure 4.4: 68aa EntV and 16aa EntV reduce biofilm biomass in vitro after 48
hours. The 16aa EntV derivative was hypothesized to have an equal inhibitory effect
against C. albicans biofilms as the 68aa EntV peptide. A) Biofilms were grown for 48
hours in YNB-AS treated with various concentrations of 68aa EntV and then stained
with crystal violet to measure biomass. The 68aa EntV peptide consistently reduced
biomass from the 100 nM to 1 nM concentrations. B) Biofilms were treated in the same
way as before with 16aa EntV, and the results similarly match the effect of the 68aa
EntV peptide. Biomass assays were analyzed by normalizing each experimental
technical replicate against the untreated mean. Results represent data collected
across three biological replicates, and a two-way ANOVA with a Dunnet’s test was
used to determine differences between the untreated control and the experimental
groups. N=6, * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001.
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The effect of the 16aa EntV peptide against biofilms is sequence specific
As before in Chapter 3, two alternative 16aa peptides with rearranged amino
acid sequences were used to test the sequence and shape specificity of the inhibitory
effect by the 16aa EntV peptide. Briefly, the disordered peptide consists of the same
amino acids and has the same overall charge as the 16aa EntV peptide, but this
engineered peptide has minimal secondary structure. The helical peptide also has
these properties but additionally has been redesigned such that it forms a helix similar
to the 16aa EntV peptide but with a distinct amino acid sequence. A more detailed
description of these peptides can be found in Figure 3.3.
Neither of the two engineered variant peptides showed any inhibitory effect
against C. albicans biofilm development (Figure 4.5). While the unaltered 16aa EntV
peptide reduced biofilm biomass by approximately 21% at the 100 nM concentration,
the disordered and helical engineered peptides at the same concentration only reduced
biomass by approximately 1.5% and 4%, respectively (Figure 4.5C). Furthermore,
neither engineered peptide at any tested concentration level produced a statistically
significant result (Figure 4.5A and B). This demonstrates that the inhibitory effect of the
16aa EntV peptide is sequence specific.
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Figure 4.5: The 16aa EntV peptide has a sequence-specific inhibitory effect on C.
albicans biofilm development. To test the sequence specificity of the interaction with
the 16aa EntV peptide, two alternative peptides were designed using reordered
sequences of the same amino acids as the 16aa EntV peptide. A) Biofilms were grown
for 48 hours in YNB-AS treated with various concentrations of an engineered
disordered peptide and then stained with crystal violet to measure biomass. This
peptide was ineffective in biofilm inhibition. B) Biofilms were treated in the same way
as before with an engineered helical peptide, and this peptide had no effect on biofilm
development. C) Data from parts A and B were compared against the data presented
in 4.4B. Biomass assays were analyzed by normalizing each experimental technical
replicate against the untreated mean. Results represent data collected across three
biological replicates, and a two-way ANOVA with a Dunnet’s test was used to
determine differences between the untreated control and the experimental groups.
N=6, * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001.
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EntV biofilm inhibition is unique amongst bacteriocins
To determine the specificity of the biofilm inhibition interaction with EntV
amongst other naturally occurring peptides, I tested two other bacteriocins similar to
EntV, Sam57 and YpkK, in the biomass assay. Previous results in this body of work
have shown that these peptides do not inhibit C. albicans growth and only have minor
efficacy in inhibiting adhesion (Figure 3.4).
Figure 4.6 depicts the results of the biomass assays with Sam57 and YpkK.
Treatment with the Sam57 bacteriocin at 100 nM produced a slight, although highly
statistically significant, reduction in biomass of approximately 10% (Figure 4.6A). This
slight effect only present at higher concentrations is consistent with the results from the
adhesion assay performed with Sam57 in Figure 3.4A. The biofilms treated with YpkK
exhibited a uniform inhibition of approximately 6% across all concentrations tested
(Figure 4.6B). Neither of the alternative bacteriocins were as potent as the 68aa EntV
peptide (Figure 4.6C). Overall, from these experiments it can be concluded that the
alternative bacteriocins Sam57 and YpkK have minimal effect on C. albicans biofilm
development, and thus the activity of EntV is due to a specific interaction with C.
albicans.
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Figure 4.6: Similar bacteriocins Sam57 and YpkK are less effective than EntV at
inhibiting biofilm development. To determine the specificity of interaction between
EntV and C. albicans, naturally occurring bacteriocins similar to EntV were tested for
activity inhibiting biofilm formation. A) Biofilms were grown for 48 hours in YNB-AS
treated with various concentrations of Sam57 and then stained with crystal violet to
measure biomass. B) Biofilms were treated in the same way as before with YpkK. C)
Data from parts A and B were compared against the data presented in 4.4A. Biomass
assays were analyzed by normalizing each experimental technical replicate against the
untreated mean. Results represent data collected across three biological replicates,
and a two-way ANOVA with a Dunnet’s test was used to determine differences
between the untreated control and the experimental groups. N=6, * P < 0.05, ** P <
0.01, *** P < 0.001, **** P < 0.0001.
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Efficacy of smaller EntV peptides
To further optimize the EntV derived peptides for biofilm inhibition, the 12aa,
11aa, 10aa, and 9aa EntV derived peptides were tested in the biomass assay. A
thorough description of the amino acid sequence and secondary structure of these
peptides can be found in Figure 3.7. Previous data presented in this body of work
showed that the 12aa EntV peptide had an efficacy profile similar to that of the 16aa
EntV peptide in reducing adhesion to an abiotic substrate. The 11aa and 10aa
peptides were less effective, and inhibition activity was lost upon further trimming to
9aa (Figure 3.7E).
Figure 4.7 depicts the data from the biomass assays with the 12aa – 9aa
peptides. These data extend the trend established in the previous chapter. Once
again, the 12aa EntV peptide shows potent efficacy, similar to the 16aa EntV peptide.
The 100 nM treatment with 12aa EntV showed the best inhibition of any of the peptides
tested in this work with a mean difference of approximately 30%. Like the 16aa EntV
peptide, the effect was consistent with treatment concentrations of 10 nM and 1 nM,
and only at 0.1 nM did the inhibition decrease to approximately 17% (Figures 4.7A and
E). The 11aa EntV peptide was less effective than the 12aa EntV peptide with a mean
inhibition of only approximately 22% from the 100 nM treatment, but the reduction in
efficacy at 0.1 nM was consistent (Figures 4.7B and E)
In the adhesion assay, the 10aa EntV peptide showed similar efficacy to the
12aa EntV peptide at high concentrations (Figure 3.7E), but it was less effective in the
biomass assays. The 100 nM treatment with the 10aa EntV peptide produced a mean
difference of approximately 15%, with only minimal differences at other concentrations
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(Figures 4.7 C and E). The 9aa EntV peptide was ineffective at inhibiting biofilm
formation at any tested concentration (Figures 4.7D and E).
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Figure 4.7: Inhibition of biofilm development by small EntV peptides. To
determine an optimal size of the EntV peptide for further study, small peptides ranging
from 12 to 9 amino acids were tested in the biofilm biomass inhibition assay. Biofilms
were grown for 48 hours in YNB-AS with various concentrations of the 12aa EntV
peptide (A), 11aa EntV peptide (B), 10aa EntV peptide (C) or 9aa EntV peptide (D). To
directly compare the efficacy of these peptides, E) the mean biomass relative to the
untreated control is displayed. Biomass assays were analyzed by normalizing each
experimental technical replicate against the untreated mean. Results represent data
collected across three biological replicates, and a two-way ANOVA with a Dunnet’s test
was used to determine differences between the untreated control and the experimental
groups. N=6 (12aa) or N=5 (11aa, 10aa, 9aa), * P < 0.05, ** P < 0.01, *** P < 0.001,
**** P < 0.0001.
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The effect of small EntV peptides on biofilm structure
The small peptides were examined for their effects on the structure of C.
albicans biofilms using microscopy as before. These results taken along with the
biomass assays provide a more comprehensive understanding of the efficacy of these
peptides. The next four figures display the results of this analysis. All the following
images were successfully deconvoluted.
Figure 4.8 depicts biofilms treated with the 12aa EntV peptide at a concentration
of 300 nM. These biofilms, especially in comparison to the untreated samples in Figure
4.1, are remarkably consistent in their size and structure. The flattening effect that was
found as a result of treatment with the 68aa EntV and 16aa EntV peptide is consistently
present in all these samples. Figures 4.8C and D depict a biofilm that appears
somewhat disorganized and lacking cohesion, a trait consistent with the previously
analyzed biofilms, however, this is not true of the other biofilms in this sample.
Biofilms treated with the 11aa EntV peptide are depicted in Figure 4.9. Once
again, a flattening effect can be observed, but it is less apparent than with treatment
from the 12aa EntV peptide. The biofilms in Figures 4.9A-D appear generally regular
with some flattening. Notably, previous treated biofilms have displayed a folding over
effect, while the hyphae in these images appear to be primarily growing a straight,
consistent angle from the yeast bed. The biofilm depicted in Figures 4.9E and F shows
characteristic disorder and flattening as has been seen previously. Figures 4.9G and H
were included to show a representative image of variation found amongst the samples
collected for this study. This biofilm still shows some flattening, but it is close to
approximately the same size as some of the smaller untreated biofilms.
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Figure 4.10 depicts biofilms treated with the 10aa EntV peptide. These biofilms
had a substantial amount of variability in their structures. The biofilm in figure 4.10A
and B appears to be significantly flattened with horizontal and disorganized hyphae.
Overall, this biofilm looks similar to biofilms treated with the 68aa and 16aa EntV
peptides. The biofilm in Figures 4.10C and D also displays characteristic flattening, but
the hyphal layer is more cohesive. The biofilms in Figures 4.10E-H are larger with
dense hyphae. Figures 4.10 E and F show disorganization while Figures 4.10G and H
show a slight flattening effect.
Lastly, Figure 4.11 depicts biofilms treated with the 9aa EntV peptide. These
biofilms look most similar to the untreated biofilms in Figure 4.1. The first two biofilms
in Figures 4.11A-D display the large size and vertical hyphae of a healthy biofilm. The
biofilms in Figures E-H are large and dense. Figures 4.11 G and H shows a small
amount of flattening, which is consistent with the finding from the biomass assay that at
high concentrations the 9aa EntV peptide has a very slight effect.
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Figure 4.8: 12aa EntV is a potent inhibitor of biofilm development.
Representative three-dimensional fluorescence microscopy images of C. albicans
CEGC1 biofilms treated with 300 nM 12aa EntV. These biofilms were grown statically
for 48 hours at 37°C in YNB-AS media with 12aa EntV and then washed. Microscopy
was performed using z-stacked images at 20x magnification with 101 frames and 3 µm
between each frame, creating a total image 300 µm in depth. Images were
deconvoluted using cellSens Dimension 2.3 (Olympus) to increase resolution.
Horizontally adjacent figures represent different perspective views of the same image.
A and B) This biofilm appears to be flattened with hyphae the grew at an angle out of
the yeast bed layer. C and D) This biofilm appears disorganized and lacking cohesion.
E and F) This biofilm is flattened. G and H) This biofilm is flattened and appears to
have hyphae that initially grew vertically out of the yeast bed layer before laying over
horizontally.
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Figure 4.9: Biofilms treated with 11aa EntV. Representative three-dimensional
fluorescence microscopy images of C. albicans CEGC1 biofilms treated with 300 nM
11aa EntV. These biofilms were grown statically for 48 hours at 37°C in YNB-AS
media with 11aa EntV and then washed. Microscopy was performed using z-stacked
images at 20x magnification with 101 frames and 3 µm between each frame, creating a
total image 300 µm in depth. Images were deconvoluted using cellSens Dimension 2.3
(Olympus) to increase resolution. Horizontally adjacent figures represent different
perspective views of the same image. A – D) These two biofilms appear to be
flattened and have hyphae that grew at a generally consistent angle out from the yeast
layer. E and F) This biofilm appears to be disordered and flattened. G and H) This
large biofilm was included to show a representative image of the variation in the sample
collected in the study. This biofilm shows some flattening with the uppermost hyphae
appearing to lay flat over the rest of the structure.
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Figure 4.10: Biofilms treated with the 10aa EntV peptide. Representative threedimensional fluorescence microscopy images of C. albicans CEGC1 biofilms treated
with 300 nM 10aa EntV. These biofilms were grown statically for 48 hours at 37°C in
YNB-AS media with 10aa EntV and then washed. Microscopy was performed using zstacked images at 20x magnification with 101 frames and 3 µm between each frame,
creating a total image 300 µm in depth. Images were deconvoluted using cellSens
Dimension 2.3 (Olympus) to increase resolution. Horizontally adjacent figures
represent different perspective views of the same image. A and B) This biofilm was
flattened and showed some disorganization. C and D) This biofilm was flattened but
appears to be generally orderly and cohesive. E and F) This biofilm is large and
generally disorganized. G and H) This biofilm was slightly flattened.
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Figure 4.11: The 9aa EntV peptide does not disrupt biofilm structure.
Representative three-dimensional fluorescence microscopy images of C. albicans
CEGC1 biofilms treated with 300 nM 9aa EntV. These biofilms were grown statically
for 48 hours at 37°C in YNB-AS media with 9aa EntV and then washed. Microscopy
was performed using z-stacked images at 20x magnification with 101 frames and 3 µm
between each frame, creating a total image 300 µm in depth. Images were
deconvoluted using cellSens Dimension 2.3 (Olympus) to increase resolution.
Horizontally adjacent figures represent different perspective views of the same image.
A – D) These two biofilms are large with hyphae that grow vertically out of the yeast
bed. E and F) This biofilm is large and dense. G and H) This biofilm is large, dense,
and generally cohesive. This biofilm appears to be slightly flattened on top.
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Discussion
The 68aa EntV peptide has been tested for efficacy in inhibiting the development
of C. albicans biofilms in prior publications by other members of our lab. The results I
have presented in Figures 4.2 and 4.4 use different techniques than what has
previously been published, and my results agree with previous findings that the 68aa
EntV peptide inhibits biofilm development and reduces biofilm size.
The biomass assay of the biofilms treated with the 16aa EntV peptide provide a
verifiable result to show that the 16aa EntV peptide has a comparable effect on biofilm
development to the 68aa EntV peptide (Figure 4.4). Both treatments reduced biomass
by greater than 20% and only had a decrease in efficacy at the 0.1 nM concentration.
Furthermore, biofilms treated with either the 68aa or 16aa EntV peptide showed
structural similarities such as a characteristic flattening effect (Figure 4.2 and 4.3).
Taken together, these results indicate that the C-terminal helix of EntV is sufficient to
elicit the same inhibitory response on C. albicans biofilms as the full 68aa peptide.
The inhibitory action is sequence specific to EntV, indicating a specific
interaction, as evidenced by the inefficacy of the reordered 16aa peptides in Figure 4.5.
Additionally, this interaction is specific to EntV. Sam57 and YpkK, bacteriocins with
size and structural similarities to EntV, had minimal to no effect on biofilm biomass
(Figure 4.6). In the previous chapter these bacteriocins were shown to have some
efficacy in inhibiting C. albicans adhesion, although they were less effective than EntV.
The inability of these bacteriocins to inhibit biofilm formation provides insight into a) the
robustness of C. albicans biofilm formation, and b) the high level of specificity of the
EntV peptide.
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The result that the 12aa EntV peptide was more effective than the shorter
peptides is internally consistent with the adhesion assay results in this same work
(Figure 3.7), and externally consistent with in vivo infection model results from the
Garsin and Lorenz labs. However, it was surprising that the 12aa EntV peptide was
much more effective than the 16aa EntV peptide in reducing biomass. In the adhesion
assays in the previous chapter, these two peptides had virtually identical efficacy
profiles for concentrations between 100 nM and 0.1 nM (Figures 3.7E). A potential
explanation for the superior efficacy of the 12aa EntV peptide in these assays is the
instability predicted in the 16aa EntV peptide as described in Figure 3.1. This instability
may also explain the unique spreading characteristic of the data for low concentration
treatments of the 16aa EntV peptide in both the adhesion assay (Figure 3.2C) and the
biomass assay (4.4B).
In total, the results in this chapter indicate that the 12aa EntV peptide is an
optimal choice for further study into biofilm inhibition of C. albicans. In this work I chose
to grow biofilms under static conditions on level surfaces to maximize reproducibility
and the resolution of images I could collect with fluorescence microscopy. However,
the most medically relevant biofilms, such as those that occur on central line catheters
or dental implants, exist in dynamic environments on uneven surfaces. Future studies
with this peptide should include an examination of its efficacy in the central line catheter
model with our collaboration with Dr. David Andes. It would also be informative to
examine the effect of treatment with the peptide to a biofilm under continuous media
flow conditions to measure the structural integrity of the biofilm and the rate of
production of disperser cells.
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I employed new and innovative technologies to obtain the results in this chapter.
Recent publications from our lab and other leaders in the field (15, 72) have compared
biofilms using two-dimensional biofilm cross-sections similar to y-axis view presented in
this work. The three-dimensional high-resolution topographical images in this work
provided enlightening additional context to the structures of these biofilms.
Additionally, for the biomass assays, an automatic Microplate washer was used to
perform the washes. When removing excess dye from a biofilm, the standard across
the field is to wash the sample by hand with a pipette (180). By using the automated
washer, I at least tripled throughput of the assay and saved plastic waste. The
methods and protocols I developed are available for future work that will allow our lab
to better understand biofilm structure and conduct large scale screens of biofilms grown
under different conditions.
As a final note, it is worth addressing that there is a significant amount of
variation in the sizes of some of the biofilms measured by confocal microscopy. This is
particularly true of the untreated biofilms presented in Figure 4.1. The biofilms treated
with the EntV peptides showed less variation in size, the most consistent of these being
the biofilms treated with the 12aa EntV peptide. An explanation for this is that normal
biofilm size exhibits a degree of stochastic variation. For biofilms treated with the
effective peptides, this variation is reduced by the treatment. This kind of variation and
relationship between healthy and unhealthy biofilms has been documented in other
previous studies (57, 72, 192, 193). In this study I used a measure of biomass to
compensate for the immutable variation of visual measurements, but another
alternative measurement used for the same reason is dry mass of a biofilm (193).
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Chapter 5: Hyphal invasion of epithelial cells is inhibited by EntV in an ex vivo
co-culture assay
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Introduction
Commensal colonization by C. albicans becomes invasive disease when the
fungal cells cross a tissue surface. One method by which C. albicans can invade host
epithelial tissue is endocytosis, whereby the host epithelial cell initiates internalization
of the fungal cell (194–196). Hyphae are more potent at causing this response, as a
non-filamentous Δ/Δ efg1/efg1 mutant has been found to be less efficient at inducing
endocytosis than wild-type cells (197). A potential explanation for this is that Als3, a
hyphal cell wall protein and adhesin, can induce endocytosis by binding to E-cadherin
and N-cadherin on host cells (5). C. albicans can also directly penetrate epithelial cells
(196, 198). Hyphae puncture host cells using physical force and several secreted
hydrolases including aspartyl proteinases, phospholipases, and lipases (199–201).
In this chapter I examine the activity of 68aa EntV and the C-terminal derived
16aa EntV peptides in inhibiting C. albicans virulence in an ex vivo tissue culture
model. In this model, C. albicans cells were cocultured with a confluent single layer of
human pharyngeal carcinoma cells (FaDu). Invasion of the host cell layer by C.
albicans hyphal cells was measured as a proxy for virulence. I hypothesized that the
C-terminal derived 16aa EntV peptide would be equally or more potent at inhibiting C.
albicans invasion into the FaDu cell layer.
The FaDu cell line originated from a 56-year-old male patient who presented to a
hospital in Calcutta in 1968 with a pharyngeal squamous cell carcinoma. This was only
the third established oral or pharyngeal epidermal cell line, the other two being KB and
Hep-2. When first described, FaDu cells were notable for their ability to grow into even
and confluent monolayers (202). Infection assays with FaDu cells have been
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previously done with C. albicans (203) and a wide range of other pathogens including
adenoviruses (204) and Neisseria meningitidis (205).
The data presented in this section remain preliminary. This model contains a
complex system of interactions between host cells, fungal cells, and media conditions,
and some of the variables were difficult to control. Thus, replication of the results
presented was inconsistent. Further research will be necessary to modify the technical
aspects of the assay to improve reproducibility. Nevertheless, the results presented
indicate potential for future success with this virulence model.
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Results
To test the activity of the 68aa EntV and 16aa EntV peptides in inhibiting ex vivo
tissue invasion, I developed a FaDu invasion assay. A confluent layer of FaDu cells
was grown in 8-well chamber slides (Ibidi), treated with EntV peptides at a
concentration of 300 nM, and co-incubated with C. albicans strain JRC58B. This fungal
strain constitutively transcribes the gene for the fluorescent protein mCherry from the
ACT1 promoter (ACT1p-mCherry). After a 2-hour co-incubation at 37°C in a 5% CO2
humidified incubator, the cells were fixed with paraformaldehyde and stained with
NucBlue and a polyclonal anti-Candida-FITC antibody. Fluorescence microscopy
images were taken an analyzed manually.
To interpret the final presentation of this data, green fluorescent signal depicts
C. albicans cells that were on the surface of the epithelial cell layer and were
accessible to the antibody stain. While all the ACT1p-mCherry C. albicans cells
produce mCherry and are visible in the red fluorescent signal, cells that are exclusively
visible with the red fluorescent signal are those that have invaded the host cell layer.
Lastly, the blue fluorescent signal depicts the nuclei of the FaDu cells.
Figure 5.1 depicts representative images of FaDu cell layers infected with the
ACT1p-mCherry C. albicans strain and a numerical comparison of hyphal and invasion
frequency between treatment conditions. In the untreated co-cultures (Figures 5.1A
and B), more than 80% of all the C. albicans cells formed hyphae (Figure 5.1G), and
subsequently many of those hyphae invaded into the cell layer. Figure 5.1A depicts a
region of the cell layer more densely populated with C. albicans cells than Figure 5.1B,
but the trend of near universal hyphal formation is consistent. For these two figures,
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approximately half of the total C. albicans cells formed hyphae that invaded into the
host cell layer (Figure 5.1H).
Figures 5.1C and D depict co-cultures treated with 300 nM 68aa EntV peptide.
Approximately half of the C. albicans cells treated with the 68aa EntV peptide formed
hyphae (5.1G), which is significantly fewer than in the untreated sample, but this did not
translate to a significant reduction in invasion (5.1H). The 16aa EntV peptide was also
effective in reducing hyphae in these cocultures (Figures 5.1E, F, and G). Additionally,
the 16aa EntV peptide treatment significantly reduced invasion by approximately 27%
from the untreated control (p-value = 0.0030, **) and 20% from the 68aa EntV treated
samples (p-value = 0.0176, *) (Figure 5.1H).
These results remain incomplete and in need of replication and further study,
however they do indicate that EntV and the C-terminal helix thereof are potentially
capable of inhibiting invasion and virulence in this ex vivo model. Furthermore, these
data indicate the potential that the 16aa EntV peptide is superior in activity to the 68aa
EntV peptide.
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Figure 5.1: The C-terminal helix of EntV inhibits hyphal formation and epithelial
invasion in an ex vivo co-culture assay. The 68aa EntV and C-terminus derived
16aa EntV peptides were tested in an epithelial co-culture model for inhibition of
invasion and virulence. In this model, co-cultures of ACT1p-mCherry and a confluent
layer of pharyngeal epithelial cells (FaDu cells) were fixed and stained with NucBlue
and an anti-Candida-FITC antibody. Hyphae that invaded into the FaDu cell layer were
unstained by the antibody (red fluorescent signal) while yeast and hyphae resting on
the cell surface were exposed to the antibody (green fluorescent signal). A and B) In
untreated co-cultures, C. albicans readily formed hyphae and invaded the FaDu cell
layer. C and D) Co-cultures treated with 300 nM 68aa EntV had fewer hyphal cells
than untreated co-cultures. E and F) Treatment with 300 nM 16aa EntV reduced both
hyphal development and invasion into the epithelial layer. G) C. albicans cells were
counted manually, and the number of hyphal cells was divided by the number of total
cells. H) The number of hyphal invasion events was divided by the number of total C.
albicans cells. Numerical results represent data collected from two separate biological
replicates, each with two technical replicates. Statistics were determined using a oneway ANOVA with a Tukey’s test with a single pooled variance to compare the mean
values of each group. N=3, * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001.
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Discussion
The results in this chapter remain preliminary due to technical difficulties.
Therefore, these results are best interpreted as potential trends. From the data
presented in this chapter, 68aa EntV has the potential to inhibit C. albicans hyphal
formation in the FaDu co-culture model. The 16aa EntV peptide also has the potential
to inhibit hyphal formation and additionally reduce C. albicans invasion into the
epithelial cell layer. Further work is necessary to improve the technical aspects of this
assay, and future studies should include analyses of other peptides previously
discussed in this work (Chapter 3), particularly the small 12aa – 9aa EntV peptides.
The technical difficulties in replicating this data produced both over- and understimulation of hyphal development in the assay. This creates confounding factors if
hyphae never form in the co-culture or form too rapidly such that the C. albicans cells
germinate before coming in contact with the FaDu cell layer. Despite these issues, the
data and model presented here remain important for this work because the interaction
of C. albicans cells with a confluent epithelial cell layer substrate most closely simulates
the conditions that exist in the human or murine host with oropharyngeal candidiasis.
To further improve the assay and potentially increase reproducibility, the co-culture
media could include mucin and co-culture could be performed under continuous flow
conditions to simulate the dynamic oral environment. This would better elucidate
differences between adhered and unadhered C. albicans cells than is possible under
static co-culture conditions.
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Chapter 6: Discussion
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Efficacy of C-terminal derived peptides
The central hypothesis of this work was that small peptides derived from the Cterminal central helix of EntV would have equal to improved efficacy in inhibiting C.
albicans in vitro biofilm formation and ex vivo virulence. In Chapter 3, these peptides
were tested for efficacy in inhibiting adhesion to an abiotic substrate, the first step in in
vitro biofilm formation. C-terminal derived 16aa and 12aa EntV peptides were found to
have increased potency in inhibiting adhesion compared to the 68aa EntV peptide
(Figure 3.7E).
In Chapter 4, the biomass and architecture of mature biofilms treated with the
peptides were analyzed. Biofilms treated with the C-terminal derived 16aa and 12aa
EntV peptides showed characteristic structural alterations consistent with biofilms
treated with the 68aa EntV peptide (Figures 4.2, 4.3, and 4.8). These structural
alterations included a general flattening effect and disorganization of the upper layers
of the biofilm. Additionally, the mature biofilms grown in media containing either the
68aa EntV or 16aa EntV peptides had similarly reduced biomasses (Figure 4.4). The
12aa EntV peptide outperformed either of these other two in reducing mature biofilm
biomass (Figure 4.7A). Lastly, the preliminary results presented in Chapter 5 indicate
that the 68aa EntV and 16aa EntV peptides have the potential to inhibit C. albicans
hyphal formation in an ex vivo epithelial cell invasion model. Furthermore, the 16aa
EntV peptide was found to have the potential to inhibit invasion into the epithelial cell
layer in this model (Figure 5.1).
Taken together, the results from the three previous chapters strongly indicate
that the C-terminal helix of EntV is a potent inhibitor of C. albicans biofilm formation and
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virulence with overall superior efficacy in these assays compared to the 68aa EntV
peptide. The peptide of optimal efficacy and minimal size in these assays was
determined to be the 12aa EntV peptide. Determining an optimal peptide of minimum
size is important for development for potential future applications. The 68aa EntV
peptide is too large to become a viable pharmaceutical product, but the size of the
12aa EntV peptide is more in accordance with other antimicrobial peptides currently in
clinical use or under investigation (101). An additional advantage of identifying the
minimal size effective peptide is that because the 12aa EntV peptide omits the amino
acid residues that are predicted to form the N-terminal tail of the 16aa EntV peptide, the
12aa EntV peptide is predicted to have a more stable helical structure (Figure 3.6).
Translating to in vivo work
Prior to the results presented in this work, in vivo C. elegans infection assays
were performed with the small 12aa – 9aa EntV peptides. These assays (unpublished)
found that the 12aa EntV peptide inhibited C. albicans virulence with the same potency
as the 16aa and 68aa EntV peptides. The 11aa and 10aa EntV peptides showed less
efficacy, and the 9aa EntV peptide was ineffective in inhibiting virulence (M. Cruz and
D. Garsin, personal communication). The general trend of these results concurs with
the results presented in this work summarized in Figures 3.7E and 4.7E.
These data informed further in vivo experiments in a murine oropharyngeal
candidiasis (OPC) model. In this infection model, mice are given a sublingual
inoculation of C. albicans and allowed to drink freely from a 100 nM peptide solution in
water. The mice are later euthanized, and the tongues are excised and analyzed for
fungal burden and histology. In this model the 12aa EntV peptide virtually eliminated
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fungal burden and performed as well as the 68aa EntV and 16aa EntV peptides.
Additionally, in agreement with my in vitro experiments and the previous in vivo C.
elegans infection assays, the 11aa and 10aa EntV peptides were less effective at
inhibiting virulence in the murine OPC model, and the 9aa EntV peptide was ineffective
at inhibiting virulence (G. Buda de Cesare, M. Cruz, and S. Guha, personal
communication).
An examination of important residues
Prior to the start of this work, C. elegans infection assays performed in the
Garsin lab showed that the cysteine residue at position 15 of the 16aa EntV peptide is
necessary for activity (M. Cruz and D. Garsin, personal communication). I
hypothesized that the only other two polar amino acid residues in the 16aa EntV
peptide, the glutamine residues at positions 7 and 14, were necessary for activity.
Contrary to my hypothesis, the results summarized in Figure 3.5E indicate that these
glutamine residues are not strictly necessary for activity. The Q – I peptide replaced
these with isoleucine residues, and the activity was mostly unchanged. Only when the
glutamine residues were altered to oppositely charged glutamate residues (Q – E
peptide) was activity lost. This finding is consistent with results from the testing these
peptides in the C. elegans infection model (M. Cruz and D. Garsin, personal
communication).
The residues of the EntV peptide essential for activity remain unknown. To
address this question in a follow up study, an alanine scan will be performed on the
12aa EntV peptide. An alanine scan is a well-established technique to identify
important residues whereby each amino acid of a peptide is mutated to an alanine and
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the peptide is tested for a change in activity. Alanine is used as the replacement
because it has a small, nonpolar sidechain and typically does not alter secondary
structure (206–208). Activity will be measured by multiple methods including the C.
elegans infection assay and the in vitro biofilm assays described in this work.
Determination of mechanism of action
An understanding of the important residues of the EntV peptide may provide
some insight into the identity of the fungal binding partner EntV interacts with.
However, determining the mechanism of action will likely require the use of multiple
techniques including the identification of resistant mutants and determining the
localization of EntV in interaction with C. albicans.
A previous graduate student in our lab, Carrie Graham, Ph.D., tested a library of
C. albicans homozygous mutants for biofilm formation when treated with supernatant
collected from overnight cultures of E. faecalis. 24 transcription factor mutants and 15
cell wall protein mutants were identified that showed resistance to the supernatant
treatment (209). E. faecalis supernatant, while a potent inhibitor of C. albicans biofilm
formation, contains numerous factors that could interact with C. albicans, many of
which are unknown. To refine this assay, it should be repeated with the 12aa EntV
peptide. Additionally, many more mutants can be tested with the high-throughput
biofilm assay I developed. Once resistant mutants are identified, precise proteinprotein interaction experiments can be performed to determine the exact binding
partner and kinetics of the interaction (210).
Localization experiments of the 68aa EntV peptide interacting with C. albicans
have previously been performed using a variant of the 68aa EntV peptide with a C-
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terminal FITC tag. Currently unpublished results have shown localization of EntV to the
cell surface of C. albicans (Y. Chebaro and M. Lorenz, personal communication). I
performed this same experiment using live C. albicans cells incubated at 37°C in
various media. I replicated these results with the additional finding that the 68aa EntVFITC peptide preferentially localizes to hyphae and appears to exhibit some
cooperativity when binding (results unpublished). These results have been replicated
by other members of the lab using fixed C. albicans cells (G. Buda de Cesare and M.
Lorenz, personal communication). The findings suggest that EntV interacts with a
factor on the surface of C. albicans cells that is either more abundant or more exposed
on the surface of hyphae than of yeast.
Further localization experiments could examine aberrant localization of the 68aa
EntV-FITC peptide with mutants identified by an in vitro biofilm screen performed with
the 12aa EntV peptide. Additionally, larger biofilm structures could be analyzed for
EntV localization using the microscopy techniques I employed to examine biofilms in
Chapter 4. Addition of the 68aa EntV peptide to biofilms already grown for 24 hours
has previously been shown to reduce final biofilm biomass after 48 total hours of
incubation (15). Determining EntV localization in these biofilms would investigate the
permeability of C. albicans biofilms to EntV and the distribution of the EntV peptide
across the heterogeneous biofilm structure.
Future Development
The broad goal of the EntV project is to determine if EntV can be turned into
something suitable for pharmaceutical use to treat or prevent C. albicans infections.
Future research into the pharmaceutical potential of EntV will involve chemically
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modifying the 12aa EntV peptide to balance three important factors: potency, stability,
and toxicity.
EntV has proven to be highly potent in our in vivo experiments thus far. Subnanomolar concentrations of the 68aa EntV peptide have been protective in the C.
elegans infection assay (15). However, this may not necessarily translate to potency in
humans, so improving the activity of the peptide should be a priority. Current work in
our lab is underway to produce a library of amino acid variants on the pattern of the
11aa and 10aa EntV peptides. These peptides have shown suboptimal efficacy in the
in vitro biofilm assays in this work (Figures 3.7 and 4.7), the in vivo C. elegans infection
assay (unpublished data), and the murine oropharyngeal candidiasis model
(unpublished data). If the activity of these peptides can be improved by modifying the
peptide, then translating these modifications to the 12aa EntV peptide may further
improve potency.
Solid Phase Peptide Synthesis is being used to create a library of variant
peptides. An advantage of this technique is that because the peptides are attached to
a solid substrate, it is easy to collect, separate, and mix batches of peptides. After
each amino acid addition step, the substrate beads can be collected, separated out,
and mixed with beads from different groups for the next amino acid addition. This
technique allows for the feasible production of several hundred variant peptides and the
inclusion of unnatural amino acids (211, 212). These peptide variants will be tested in
the high throughput in vitro biofilm assay developed for this work (Chapter 4) and a
high throughput C. elegans infection assay (213).
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Research will need to be conducted into the pharmacokinetics of the 12aa EntV
peptide. Peptide drugs, especially those administered into the bloodstream, typically
have short half-lives in the body due to the action of proteases and peptidases (214).
Exopeptidases, enzymes that cleave the terminal peptide bond, are likely a significant
threat to the 12aa EntV peptide’s stability in the body because the cysteine at the Cterminus of this peptide is essential and the N-terminus cannot be reduced without a
decrease in activity. One way to mitigate this effect is to modify the N- and C- termini
(215). Another method to increase stability is to synthesize the peptide using D-amino
acids, the stereoisomers of the naturally occurring amino acids (216, 217). Lastly, for
administration into the bloodstream, it may be possible to fuse the 12aa EntV peptide to
a host protein such as albumin (218).
A correct balance between potency and stability will have to be determined while
developing this potential drug. Alterations to the amino acid sequence of the 12aa
EntV peptide could increase potency but may introduce some instability into the
remarkably stable helix. Modifications to the N- and C-termini or fusion to albumin
could significantly increase the half-life of the peptide in the body but may decrease the
peptide’s affinity for the binding site and thus its potency. The third factor to balance is
toxicity. Inclusion of unnatural amino acids, such as the D-amino acids, could make the
peptide toxic, and there are concerns about these unnatural amino acids accumulating
in the liver and other organs (219, 220).
Future applications
As a non-fungicidal attenuator of virulence, EntV is likely suitable as an additive
to existing antifungal therapy or as a preventative against infection. The potent activity
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of EntV in inhibiting adhesion and biofilm formation as demonstrated in this work
indicate this peptide may have potential in treating mucosal oropharyngeal and
esophageal infections, preventing biofilm formation on central venous catheters, and
treating disseminated infections.
Oropharyngeal / esophageal candidiasis
Oropharyngeal and esophageal candidiasis are mucocutaneous infections with
generally good prognoses. Mild oropharyngeal infections are typically treated with
topical clotrimazole in the form of a troche (throat lozenge). Moderate-to-severe cases
of oropharyngeal infection and esophageal infections are typically treated with oral
fluconazole (89). The addition of EntV to treatment of moderate-to-severe
oropharyngeal and esophageal candidiasis could clear the infection more quickly. This
could potentially be administered as a troche, mouthwash, or ingestible solution. To
test the potential for synergy between these treatments, the murine oropharyngeal
candidiasis model established in our lab could be modified. Treatment could be
withheld for 1 – 2 days to allow the infection to establish itself. Then we could treat the
infection with various combinations of EntV and fluconazole, clotrimazole, or nystatin.
Catheter-related blood-stream infections
For critically ill nonneutropenic immunocompetent patients, the use of central
venous catheters is common and is the greatest risk factor for developing candidemia
(11–13). Biofilm production by C. albicans and C. parapsilosis in these catheters
correlates with a significant increase in mortality (49). To prevent the development of
microbial colonization and biofilm formation, some central venous catheters are now

124

coated with antimicrobial agents. Unfortunately, fungal pathogens are often overlooked
in studies of the effectiveness of different coatings (221).
Of the different coatings currently available, there is not one that is perfect for
every application. Chlorhexidine/silver sulfadiazine coated catheters have been
studied for several years with conflicting results regarding their efficacy (221, 222), but
a recent meta-analysis found overall positive results indicating they decrease
colonization and blood-stream infections, including against C. albicans. The
disadvantage of these catheters is that they have a short shelf life (223). Other
coatings include silver ions, benzalkonium chloride, and minocycline/rifampicin, which
is potent against bacterial species but inadvertently increases the risk of fungal
colonization (223).
EntV could be a potential catheter coating agent that may work in concert with
some of these other catheter coatings. Our lab has established a collaboration with a
leader in the field of catheter associated C. albicans biofilm formation, David Andes,
M.D. Unpublished work examining the effectiveness of the 68aa EntV peptide in
inhibiting biofilm formation when added to the lumen of venous catheters in rats has
shown promising results. Future work with this model should include studies with the
12aa EntV peptide and coated catheters currently available on the market. The
ultimate goal of this work would be to create a shelf stable catheter that inhibits
colonization and biofilm formation from the broadest possible range of microbial
species.
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Disseminated infections
There is critical need to develop new treatments for disseminated and invasive
candidiasis. There is a paucity of drugs approved to treat these infections. Of the
drugs that have been approved, there are only three chemical classes (89), and one
these, the polyenes, carry the risk of severe adverse effects (82, 83, 87).
EntV, as an inhibitor of virulence, could be used in combination with currently
approved drugs to increase the efficacy of the treatment. This type of drug strategy
has become more prominent in recent years as the threat of antimicrobial resistance in
many different pathogenic species becomes more urgent (224–228). To investigate
this potential, our lab conducted an experiment with a murine disseminated candidiasis
model. For this experiment, C. albicans cells were grown to log phase, soaked in PBS
for one hour with either the 12aa EntV peptide or a DMSO vector control, and
administered to mice via a tail vein injection. The results of this experiment remain
preliminary, but the 12aa EntV peptide had a potent effect in reducing mortality in the
treated mice compared to the untreated control group (P. Miramon Martinez and M.
Lorenz, personal communication). Future research on this topic should include in vitro
and in vivo examinations of synergy between EntV and the approved antifungal drugs.
Evolution of EntV
The specificity of the 16aa C-terminal derived EntV peptide was tested in the in
vitro adhesion and biomass assays in Figures 3.3 and 4.5. These experiments
confirmed that the effect of the 16aa EntV peptide is specific to its helical shape and
amino acid sequence. Additionally, two bacteriocins produced by Streptococcus
pyogenes and Corynebacterium jeikeium that share similarities in size and structural
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motifs with EntV (174) were tested for efficacy in the in vitro adhesion and biomass
assays (Figures 3.4 and 4.6). These peptides were ineffective in inhibiting C. albicans
biofilm formation in these assays, indicating that attenuation of C. albicans virulence is
specific to EntV. Taken together, these results suggest that the C. albicans virulence
attenuation activity of EntV may provide some evolutionary advantage to E. faecalis.
One potential explanation for this is that E. faecalis is well adapted to live as a
commensal in the host environment. In addition to humans and other mammals, E.
faecalis colonizes distantly related animals such as insects and birds (229, 230). This
would suggest that E. faecalis was an early member of host microbiota and has had
adequate time to evolve specific adaptations to its environment (231). One such
adaptation could be to promote healthy commensal growth by inhibiting an
immunostimulatory effect from other gut commensals, such as C. albicans. Producing
a secreted factor, such as EntV, that inhibits C. albicans adhesion and hyphal formation
could reduce host inflammation by reducing fungal interaction with and recognition by
host cell pattern-recognition receptors (PRRs) (232). Therefore, the evolutionary
advantage of producing EntV for E. faecalis is protection from the host immune system.
C. albicans has many complex interactions with other microbial species
including E. faecalis, P. aeruginosa, and Streptococci (6, 7). The impetus for this
project was the observation that E. faecalis has the ability to influence C. albicans
virulence (173). However, C. albicans also influences the virulence of these bacterial
species (155, 173). Further investigation into these interactions and other
polymicrobial communities may provide useful insights into the natural world and lead
to the development of new drugs and technologies.
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Figure A.1: DMSO does not inhibit adhesion at relevant concentrations. To
rigorously ensure the DMSO vector could not be causing the inhibition effect, I tested
the 12aa EntV and 68aa EntV with extra DMSO at each concentration. In addition to a
DMSO control, I added 0.5 μl of DMSO to each peptide solution of both the PBS presoak and the YNB-AS media. This amount of DMSO is greater than what is normally in
the media but still is only at a concentration of 0.03% (v/v). The DMSO only control
had no significant inhibitory effect on adhesion, and all other peptide concentrations
match the results from Chapter 3 (Figures 3.2 and 3.7). Therefore, the DMSO vector
does not have an effect on adhesion.
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